Document:

Exclusive Distribution Agreement

  
 Exhibit 10.1

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
omissions. 
 EXCLUSIVE DISTRIBUTION AGREEMENT 
 This Exclusive Distribution Agreement (this “Agreement”) is made and entered into as of September 30, 2010 (the “Effective Date”), by and between Zimmer Dental,
Inc., a Delaware corporation (“Zimmer”), and RTI Biologics, Inc., a Delaware corporation (“RTI”). 
 Recitals 
 A. RTI prepares allograft and xenograft biologic implants for
tissue and bone repair and other surgical solutions, including the Implants (as defined below). 
 B. Zimmer distributes a
variety of dental products manufactured by itself and others. 
 C. Tutogen Medical, Inc. (a Florida corporation and subsidiary
of RTI Biologics, Inc.) and Zimmer (as a permitted successor to Sulzer Calcitek, Inc.) are currently parties to the U.S. Service Agreement dated September 29, 2000, as amended (“U.S. Agreement”); Tutogen Medical GmbH and Zimmer
(as a permitted successor to Sulzer Calcitek, Inc.) are currently parties to the Xenograft Distribution Agreement dated September 29, 2000, as amended (“Xenograft Agreement”) and the Processed Tissue Development and License
Agreement dated September 29, 2000 (“Development Agreement”); Zimmer Dental Corp. and Tutogen Medical GmbH are currently parties to the Canadian Distribution Agreement dated August 1, 2004, as amended (“Canada
Agreement”); and Zimmer and Tutogen Medical, Inc. are currently parties to the Distribution Agreement dated August 17, 2007, as amended (“International Agreement”). 

D. RTI desires to appoint Zimmer as the exclusive distributor of the Implants throughout the Territory for use in the Field (each as
defined below), and Zimmer desires to accept such appointment, in accordance with the terms and conditions of this Agreement; and 
 E. Tutogen Medical, Inc., Zimmer and/or their appropriate respective Affiliates have executed separate acknowledgements that the U.S. Agreement, Xenograft Agreement, Development Agreement, Canada
Agreement and International Agreement will each be superseded and replaced by this Agreement as of the Effective Date. 

Agreement 

In consideration of the mutual covenants contained in this Agreement, Zimmer and RTI agree as follows: 

ARTICLE I 

DEFINITIONS AND RULES OF CONSTRUCTION 
 1.1. Definitions. 
 (a) Terms Defined in this Article. For purposes
of this Agreement, including the Recitals above, the following terms shall have the following meanings: 
 “Adverse
Event” means any adverse health event to which an Implant has or may have contributed. The term is generally limited to those events that would be reportable to a Regulatory Authority; e.g., applicable reporting through MedWatch to
the FDA (U.S.) or Adverse Reaction/Vigilance Reporting to Competent Authorities (EU). 

  
 1 

  

“Affiliate” means, with respect to an entity (including either Party), a Person that directly, or indirectly through one
or more intermediaries, controls, is controlled by, or is under common control with, the entity. For this purpose, “control” of an entity means the possession, directly or indirectly, of the power to direct or cause the direction of the
management and policies of the entity, whether through the ownership of at least fifty percent (50%) of the voting interest, including securities, by contract or otherwise. 

“Agreement” means this Exclusive Distribution Agreement including its Exhibits attached hereto as such may be amended
from time to time. 
 “Applicable Industry Standards” means all applicable standards, requirements, rules and
codes of the American Association of Tissue Banks, Advanced Medical Technology Association and other industry organizations recognized by the Parties as authoritative bodies governing the conduct addressed in this Agreement. 

“Applicable Laws” means all applicable common law, statutes, ordinances, rules, regulations or orders of any
Governmental Authority, including Regulatory Laws. 
 “Business Day” means any day other than a Saturday, a
Sunday or a day on which the Federal Reserve Bank of New York is authorized or obligated by law or executive order to remain closed. 
 “Change of Control” means, with respect to an entity, a transaction or series of related transactions as a result of which a Person or group of Persons acting in concert directly or
indirectly acquires, after the Effective Date, control of the entity such that he, she, or it would either (i) meet the definition of an Affiliate or (ii) acquires ownership of all or substantially all of said entity’s assets. With
respect to RTI, a Change of Control shall also include such a transaction that transfers ownership of its product line for the Implants to another Person or group of Persons. The transaction(s) may be in any form or combination of forms, including
an issuance of voting securities, a grant of one or more proxies, a merger (whether or not the entity survives), a consolidation, a share exchange, a reorganization or an asset sale. For this purpose, “control” of an entity means the
possession, direct or indirect, of the power to direct or cause the direction of the management and policies of the entity, whether through the ownership of at least fifty percent (50%) of the voting interests, including securities, by contract
or otherwise. 
 “CPI” means the consumer price index for all urban consumers, U.S. city average for all items,
as published by the United States Department of Labor, Bureau of Labor Statistics. 
 “DBM Agreement”
means the Exclusive License and Distribution Agreement dated May 14, 2007, as amended, between Zimmer, Inc. and Regeneration Technologies, Inc., pursuant to which Zimmer, Inc. has an exclusive license to distribute products developed from
certain licensed technology involving human demineralized bone matrix (DBM) bone paste products. 

  
 2 

  
 “End
User” means the health care provider who acquires the Implants from Zimmer (or its Marketing Partner) for implantation or administration to a patient. 
 “FDA” means the United States Food and Drug Administration or any successor agency having the administrative authority to grant Marketing Approval in the United States.

 “Fees” means the tissue transfer fees (transfer pricing) to be paid by Zimmer to RTI for the Implants.

 “Field” means any and all dental and oral applications, including adjacent relevant anatomy reasonably or
commonly grafted, augmented, or reconstructed during dental and oral rehabilitation procedures, and expressly excludes ear, nose, throat and neurosurgical applications. 
 “Field Action” means any recall, product withdrawal, correction or removal action with respect to any Implants by Zimmer or RTI due to safety, efficacy, quality or regulatory compliance
concerns, including actions to recover title to or possession of, or to halt distribution of, Implants that previously have been shipped to customers. 
 “cGTPs” means current good tissue practices as specified in the Regulatory Laws of the applicable Regulatory Authority, as such Regulatory Laws are in effect at the time of manufacturing,
including without limitation, Section 361 of the Public Health Services (PHS) Act (42 U.S.C. §264), as amended from time to time, and FDA tissue regulations, including 21 C.F.R. Part 1271, Subparts C and D, as revised from time to
time. 
 “Governmental Authority” means any country in which the Implants are recovered, processed, sterilized,
stored, packaged, marketed, tested, investigated or otherwise regulated, and all states or other political subdivisions thereof and supranational bodies applicable thereto, including the European Union, and all agencies, commissions, officials,
courts or other instrumentalities of the foregoing. 
 “Implants” means the implants listed and described on
Exhibit A to this Agreement and all allograft and xenograft tissue-based bio-implants that constitute improvements, modifications, additions of new features and processing refinements, including new or improved tissue sterilization methods,
to any Implants, and line extensions. The term Implants shall not include human demineralized bone matrix (DBM) bone paste products. 
 “Insolvency Event” means that the Party has (i) commenced a voluntary proceeding under any insolvency law, (ii) had an involuntary proceeding commenced against it under any
insolvency law which has continued undismissed or unstayed for 60 consecutive days, (iii) had a receiver, trustee or similar official appointed for it or for any substantial part of its property, (iv) made an assignment for the
benefit of creditors or (v) had an order for relief entered with respect to it by a court of competent jurisdiction under any insolvency law. For purposes hereof, the term “insolvency law” means any applicable bankruptcy, insolvency
or other similar law now or hereafter in effect. 

  
 3 

  
 “Intellectual
Property” means (i) discoveries, inventions, improvements, concepts and ideas, whether or not patentable, (ii) works of authorship fixed in a tangible medium of expression, (iii) Trademarks, (iv) trade secrets and
know-how and (v) all proprietary rights relating thereto, including all applications, registrations and renewals in connection therewith. 
 “Label” means the display of written, printed or graphic matter either upon the immediate container of any article (i.e., on the outside container or wrapper, if any, of the retail
package of the article) or that is easily legible through the outside container or wrapper. 
 “Manufacture”
means all operations necessary or appropriate to process, test, package, store, sterilize, label, release and ship an Implant in accordance with industry standards, cGTPs, ISO requirements, Applicable Laws and the applicable Specifications.

 “Marketing Approval” means, with respect to any country or jurisdiction, the act of the applicable
Regulatory Authority that is necessary under applicable Regulatory Laws for the Manufacture, marketing, transfer, sale and/or Distribution of an implant or product in that country or jurisdiction, and satisfaction of all applicable regulatory and
notification requirements. 
 “Marketing Partner” means a Third Party that promotes, markets, sells and/or
distributes a Party’s implants or products under a contractual arrangement with that Party (use of the term Marketing Partner shall not imply the existence of a partnership or any other type of agency relationship). 

“Package Inserts/Instructions for Use (IFU)” means information supplied by the manufacturer of an implant or product
that includes all the information needed to use it safely. Specifications for Package Insert/IFU content vary with regulatory jurisdiction, but typically include operating instructions, warnings and/or precautions, indications, contraindications,
information relative to sterilization, instructions in the event of damage to sterile packaging, cleaning, disinfection information, etc. The Package Insert/IFU must accompany the implant or product in most jurisdictions, except in the U.S. where
electronic provision is an alternative. 
 “Parties” means Zimmer and RTI. 

“Party” means Zimmer or RTI, as the context requires. 

“Person” means any individual, group or entity, including Governmental Authorities. 

“Point of Destination” means the location within the Territory for shipment of the Implants as designated by Zimmer in
the applicable Firm Order. 
 “Regulatory Authority” means, with respect to any country or jurisdiction, any
Governmental Authority involved in granting Marketing Approval or in administering Regulatory Laws in that country or jurisdiction. 

  
 4 

  
 “Regulatory
Laws” means all Applicable Laws governing (i) the import, export, design, testing, investigation, Manufacture, sterilization, storage, distribution, marketing, transfer or sale of an implant, (ii) establishing recordkeeping or
reporting obligations for Third-Party Complaints or Adverse Events, (iii) Field Actions or (iv) similar regulatory matters. 
 “RTI IP” means all Intellectual Property that is subject as of the Effective Date, or becomes subject during the Term, to RTI’s control and that is necessary or useful for the
Manufacture, testing, use, promotion, marketing, distribution or transfer of the Implants. For this purpose, RTI shall be considered to control Intellectual Property if RTI owns or has a license to it and also has the right to sublicense marketing
and distribution rights to Zimmer. 
 “Specifications” means, with respect to each Implant, (i) RTI’s
design, functionality, processing, storing, packaging, shipping, sterilizing and labeling specifications relating to the Implant, (ii) any design, functionality, processing, storing, packaging, shipping, sterilizing or labeling specifications
described in RTI’s promotional literature and other Implant documentation made available to Zimmer and (iii) any specifications for processing, testing, storing, packaging, shipping, sterilizing or labeling the Implant set forth in any
approved application for Marketing Approval and any supplements and amendments thereto. 
 “Supply Shortfall”
means a failure of RTI to supply at least eighty-five percent (85%) of the Firm Orders submitted by Zimmer under this Agreement for a specific category of Implants (as designated on Exhibit A) for three (3) months in any
consecutive rolling nine-month period. 
 “Territory” means the entire world with the exception of the
country(ies) specifically listed on Exhibit B to this Agreement. 
 “Third Party” means any Person
other than the Parties and their Affiliates. 
 “Third Party Complaint” means any expression by a
Third Party of dissatisfaction relating to the identity, durability, reliability, safety, efficacy or performance of the Implants, including actual or suspected implant tampering, contamination, mislabeling or misformulation. 

“Trademarks” means all trademarks, service marks, trade dress, logos and trade names, together with all translations,
adaptations, derivations and combinations thereof (including all goodwill associated therewith), and all applications, registrations and renewals in connection therewith. 
 “United States” or “U.S.” means the United States of America, including its territories, commonwealths and possessions. 

(b) Terms Defined Elsewhere. Capitalized terms not defined in Section 1.1(a) shall have the meanings specified elsewhere in
the text of this Agreement. Those terms include the following: 
  

			
	 Term
	  	 Section

	Agreement	  	Opening paragraph

  
 5 

			
	 Term
	  	 Section

	Additional Order	  	3.4
	Annual Exclusivity Payments	  	4.1
	Canada Agreement	  	Recitals
	Cancellation Notice	  	12.1
	Claim	  	8.1(c)
	Commercialization License	  	8.3
	Confidential Information	  	7.1(a)
	 *******
	  	10.1
	 *******
	  	2.6(b)
	 *******
	  	2.6(a)
	Development Agreement	  	Recitals
	Distribute	  	2.1
	Distribution Rights Payment	  	4.1
	DRP Meeting	  	6.2
	Effective Date	  	Opening paragraph
	Existing Agreement Implants	  	2.2
	Existing Distribution Agreement	  	2.2
	Firm Order	  	3.6
	Forecasted Firm Order	  	3.2
	 *******
	  	3.9(e)
	Initial Term	  	12.1
	International Agreement	  	Recitals
	Material Adverse Market Change	  	4.6
	 *******
	  	3.9(e)(i)
	Minimum Requirements	  	3.9
	Non-Solicitation Period	  	13.3
	Professional Liability Claim	  	11.1(a)
	QA/RA Agreement	  	4.3
	Refunds	  	4.1(d)
	 *******
	  	2.3
	Rolling Forecast	  	3.1
	RTI	  	Opening paragraph
	RTI New Implant	  	2.8(a)
	RTI Notice	  	2.7(b)
	 *******
	  	10.2
	Supply Shortfall Period	  	2.4(b)
	Term	  	12.1
	Transition Services Agreement	  	3.5
	U.S. Agreement	  	Recitals
	Xenograft Agreement	  	Recitals
	Zimmer	  	Opening paragraph
	Zimmer New Implant	  	2.7(a)
	Zimmer Notice	  	2.8(b)

  
 6 

  
 1.2. Rules of
Construction. 
 (a) Elements of this Agreement. When a reference is made in this Agreement to a Recital, an Article,
a Section, or an Exhibit, such reference is to a Recital, Article or Section of, or an Exhibit to, this Agreement, unless otherwise indicated. 
 (b) Meaning of “Include” and Variations Thereof. Whenever the words “include,” “included,” “includes” or “including” are used in this Agreement,
they shall be understood to be followed by the words “without limitation.” 
 (c) Use of Pronouns. Pronouns,
including “he,” “she” and “it,” when used in reference to any Person, shall be deemed applicable to entities or individuals, male or female, as appropriate in any given case. 

(d) Headings. Article, Section and other headings contained in this Agreement are for reference purposes only and are not intended
to describe, interpret, define or limit the scope, extent or intent of any provision of this Agreement. 
 (e) Variation on
Terms. Standard variations on defined terms (such as the plural form of a term defined in the singular form, and the past tense of a term defined in the present tense) shall be deemed to have meanings that correlate to the meanings of the
defined terms. 
 (f) Currency. The symbol “$” means United States dollars. 

ARTICLE II 

DISTRIBUTION OF THE IMPLANTS 
 2.1. Distribution Rights. RTI hereby grants to Zimmer and its Affiliates, and Zimmer hereby accepts, the exclusive right to promote, market, transfer and distribute and/or sell (collectively,
“Distribute” or “Distribution”) the Implants throughout the Territory for all uses and applications in the Field. Zimmer shall have the right to appoint its Marketing Partners to participate in the Distribution of
the Implants in the Territory. Subject to Section 2.2 below, RTI shall not (i) directly or indirectly, Distribute, or permit Distribution of, any allograft or xenograft implants anywhere in the Territory for any uses or applications in the
Field, either on its own behalf or through any Affiliate or Third Party or (ii) license any of its proprietary tissue processing technology to any Third Party for use with allograft or xenograft implants for applications in the Field.
Except as provided for in Section 2.2, in the event RTI learns that one of its Marketing Partners is Distributing any RTI Manufactured allograft or xenograft implants anywhere in the Territory for any uses or applications in the Field, RTI will
take prompt action, including any necessary legal or equitable relief, to force such Third Party to cease such activity. 

2.2. Existing Distribution Agreement. Zimmer acknowledges that RTI currently processes certain implants (including bone paste
products containing a gelatin carrier and an osteoconductive and/or osteoinductive substance) described and listed in Exhibit C (the “Existing Agreement Implants”) for distribution by and through Exactech in the Field
pursuant to the terms and conditions of an existing agreement between RTI and Exactech (the “Existing Distribution Agreement”). The Parties acknowledge and agree that such activity, limited to the

  
 7 

 
Existing Agreement Implants, shall not be a violation of this Agreement by RTI; provided that RTI shall not, directly or indirectly, permit any Third Party other than Exactech and
Exactech’s marketing partners (as authorized by the Existing Distribution Agreement) to Distribute the Existing Agreement Implants anywhere in the Territory for any uses or applications in the Field, ********. 

2.3. Marketing and Distribution Activities. Zimmer shall have sole control and authority over its marketing activities for the
Implants. Zimmer’s marketing and distribution efforts may include development of collateral marketing materials, surgical training, attendance at professional tradeshows, and pre-clinical and clinical studies, at Zimmer’s cost. Zimmer
shall provide RTI with a reasonable opportunity to review and approve all marketing and collateral materials relating to the Implants solely for purposes of compliance with Regulatory Laws and to ensure the accurate description of RTI’s
Manufacturing processes, which approval shall not be unreasonably withheld or delayed. Zimmer shall have sole discretion to establish the transfer fee terms and other terms and conditions in connection with the Distribution of the Implants to
Zimmer’s customers. *******  
 2.4. Sole Source Provider. 

(a) RTI shall be Zimmer’s sole source provider for allograft-based tissue implants (i) comprised of the same material,
(ii) having the same application, and (iii) *******, provided RTI has the capability or capacity to meet Zimmer’s demand, failing which the provision of Section 2.4(b) shall apply. The Parties agree that RTI’s sole source
provider designation shall in no way limit or modify RTI’s obligation under this Agreement to fulfill in a timely manner all Firm Orders for Implants submitted by Zimmer in accordance with Section 3.2 and subject to Section 3.3. For
clarification purposes, the Parties further agree that the sole source provider designation shall not apply to (i) any (w) synthetic products and (x) xenograft products (other than those which are Implants), that are currently
Distributed by Zimmer, and any improvements to these products, (ii) any synthetic or collagen based products that are intended to complement or expand Zimmer’s existing portfolio of products and do not compete directly with any Implant,
(iii) any allograft or xenograft paste products, and (iv) any product Distributed by Zimmer currently or during the Term of this Agreement in the Field that is (y) currently Distributed by an Affiliate of Zimmer and any improvements
to these products, or (z) intended to complement or expand the existing portfolio of products of an Affiliate of Zimmer. 

(b) In the event of a Supply Shortfall with respect to a category of Implants, Zimmer shall have the right to utilize Third Party
suppliers for the purpose of filling its shortfall with respect to such category of Implants until such time as RTI has established, to RTI’s satisfaction and Zimmer’s satisfaction, which shall not be unreasonably withheld, RTI’s
ability to meet and maintain for the foreseeable future, capacity sufficient to meet Zimmer’s demand for such category of Implants, but in no event less than one year (the “Supply Shortfall Period”). In addition, Zimmer shall
have a reasonable period of no less than twelve (12) months following the Supply Shortfall Period during which to wind down its supply arrangement with any Third Party supplier utilized during the Supply Shortfall Period. Zimmer’s exercise
of its rights under this Section during the Supply Shortfall Period will not reduce or eliminate RTI’s obligations to Zimmer with respect to, or the resulting consequences of, an Impeding Event in accordance with Sections 3.9 and 4.1 of this
Agreement. 

  
 8 

  
 (c) On or after
January 1, 2016, nothing in this Agreement shall prohibit or limit Zimmer from developing internally or by or through a Third Party, substantially similar implants to those in Exhibit A for purposes of Zimmer’s continuity of supply
upon expiration or termination of this Agreement. 
 2.5. Branding. The Implants shall be branded as directed by Zimmer.
Zimmer shall have sole responsibility for obtaining legal protection of Zimmer private label brand names, which shall be proprietary to Zimmer. RTI shall cooperate as reasonably requested by Zimmer to obtain approval of such brand names as may be
required by Regulatory Laws (in RTI’s and/or Zimmer’s name, as determined by Zimmer). Packaging materials will utilize designs suited to RTI’s production capabilities and RTI shall maintain records of packaging specifications. Within
the physical limitations imposed by the previous sentence, packaging graphics and labeling for the Implants will be adapted by RTI as instructed by Zimmer to meet Zimmer’s branding standards. 

2.6. RTI Support of Marketing Effort. 
 (a) U.S. and Canada. In the U.S. and Canada, ********. All educational events and trade shows shall be conducted in accordance with Applicable Laws and AdvaMed guidelines. ******* 

(b) Europe, Middle East and Africa (EMEA). In EMEA, *******. All educational events and trade shows shall be conducted in
accordance with Applicable Laws. ******* 
 (c) Expenses. RTI and its Affiliate(s) shall be responsible for their own
costs and expenses incurred in connection with the marketing and distribution support activities described in this Section; provided that, Zimmer will reimburse RTI for the reasonable lodging, meals and transportation expenses of RTI’s or
RTI’s Affiliate(s)’ personnel that are necessarily incurred for travel requested by Zimmer in accordance with Zimmer’s travel policies. RTI will provide Zimmer with all documentation in support of such travel expenses as Zimmer may
reasonably require. Notwithstanding the foregoing, the Parties agree that Zimmer will not be obligated to reimburse RTI’s travel expenses relating to regular business reviews or meetings required in the normal course of business in managing the
Zimmer relationship. 
 (d) Samples. RTI shall provide Zimmer and its Affiliates and Marketing Partners with sterile and
non-sterile Implant samples (with the mix of Implants determined by Zimmer) for education and for demonstration purposes at trade shows, promotional activities, training classes and similar uses ******* 

(e) Implants for Research. On an annual basis, the Parties shall discuss and agree upon an annual needs assessment for research
projects relating to the Implants and/or new implants or indications. RTI shall provide Implants to Zimmer for research purposes for a fee to be negotiated by the Parties on a per research project basis. 

  
 9 

  
 2.7. RTI’s
Right of First Negotiation. 
 (a) Scope. RTI shall have the right of first negotiation, on the terms set forth in
this Section, if Zimmer seeks to develop and/or distribute any new allograft or xenograft implant for use within the Field (a “Zimmer New Implant”). Notwithstanding the foregoing, the Parties acknowledge and agree that the term
“Zimmer New Implant” specifically excludes, and RTI’s right of first negotiation under this Section shall not apply to, (i) any (w) synthetic products and (x) xenograft products (other than those which are Implants),
that are currently Distributed by Zimmer, and any improvements to these products, (ii) any synthetic or collagen based products that are intended to complement or expand Zimmer’s existing portfolio of products and do not compete directly
with any Implant, (iii) any allograft or xenograft paste products, and (iv) any product Distributed by Zimmer currently or during the Term of this Agreement in the Field that is (y) currently Distributed by an Affiliate of Zimmer and
any improvements to these products, or (z) intended to complement or expand the existing portfolio of products of an Affiliate of Zimmer. 
 (b) Disclosure to RTI. Prior to seeking development or supply of the Zimmer New Implant from any Third Party, Zimmer shall give RTI written notice of such Zimmer New Implant request (“RTI
Notice”). 
 (c) Response and Negotiations. Within ninety (90) days after it receives the RTI Notice, RTI
shall notify Zimmer in writing whether it is interested in pursuing a development and/or supply arrangement with Zimmer for the Zimmer New Implant. If RTI desires to develop and/or supply the Zimmer New Implant, the Parties shall begin good faith
negotiations on the terms of the development and/or supply arrangement. During the negotiations, Zimmer will continue to provide RTI with any relevant information regarding the Zimmer New Implant that RTI reasonably requests, so long as disclosure
will not cause Zimmer to breach any confidentiality obligations and Zimmer has or can acquire the requested information without unreasonable effort or expense. 
 (d) Termination of Right. If RTI notifies Zimmer that it is not interested in pursuing a development and/or supply arrangement for the Zimmer New Implant, or if Zimmer and RTI have not agreed upon
terms within ninety (90) days after Zimmer receives RTI’s written response to the RTI Notice, and if throughout that period Zimmer shall have negotiated and responded to information requests in good faith, then RTI’s right of
first negotiation shall be terminated and Zimmer shall be free to reach an agreement with a Third Party; provided that the terms and conditions agreed upon with the Third Party are not equivalent or more favorable to the Third Party than
the last written offer exchanged in the negotiations between Zimmer and RTI. 

  
 10 

  
 2.8. Zimmer’s
Right of First Negotiation. 
 (a) Scope. Zimmer shall have the right of first negotiation, on the terms set forth in
this Section, for any new allograft or xenograft implants developed by RTI (excluding any Existing Agreement Implants covered under Section 2.2) with applications in the Field (“RTI New Implant”). 

(b) Disclosure to Zimmer. Subject to Section 2.2 of this Agreement, prior to offering the RTI New Implant for distribution by
or through any Third Party, RTI shall first notify Zimmer by written notice (“Zimmer Notice”). 
 (c)
Response and Negotiations. Within ninety (90) days after it receives the Zimmer Notice, Zimmer shall notify RTI in writing whether it is interested in pursuing an distribution arrangement with RTI for the RTI New Implant. If Zimmer desires
to Distribute the RTI New Implant, the Parties shall begin good faith negotiations on the terms of the distribution arrangement. During the negotiations, RTI will continue to provide Zimmer with any relevant information that Zimmer reasonably
requests, so long as disclosure will not cause RTI to breach any confidentiality obligations and RTI has or can acquire the requested information without unreasonable effort or expense. 

(d) Termination of Right. If Zimmer notifies RTI that it is not interested in pursuing a distribution arrangement for the RTI New
Implant, or if Zimmer and RTI have not agreed upon terms within ninety (90) days after RTI’s receipt of Zimmer’s response to the Zimmer Notice, and if throughout that period RTI shall have negotiated and responded to information
requests in good faith, then Zimmer’s right of first negotiation shall be terminated and RTI shall be free to reach an agreement with a Third Party; provided that the terms and conditions agreed upon with the Third Party are not
equivalent or more favorable to the Third Party than the last written offer exchanged in the negotiations between Zimmer and RTI. 
 ARTICLE III 
 TISSUE TRANSFER ORDERS 

3.1. Forecasts and Distribution Summaries. Zimmer shall use commercially reasonable efforts to provide to RTI
rolling forecasts, broken down by Implant code, of the anticipated quantities of the Implants that Zimmer expects to order (the “Rolling Forecast”). The Rolling Forecasts will be updated monthly on or before the fifth (5th) Business Day of each month and will show anticipated monthly
orders for a period of at least twelve (12) consecutive calendar months, with the first month of each Rolling Forecast being the first full calendar month subsequent to the date on which the then current Rolling Forecast is due, e.g. a
Rolling Forecast due by February 5 shall begin with the month of March. The Rolling Forecasts will be non-binding and for planning purposes only. In addition, Zimmer will provide RTI with a monthly summary of the number of Implants distributed
by Zimmer and its Affiliates and Marketing Partners in the prior month. 
 3.2. Firm Orders. On or
before the fifth (5th) Business Day of each month,
Zimmer shall place binding firm tissue transfer orders with RTI for the Implants covering ****** of Zimmer’s Rolling Forecast, with requested delivery dates no less than the lead time set forth on

  
 11 

 
Exhibit A for the applicable Implants (each, a “Forecasted Firm Order”). In the event there is a discrepancy between the submitted Rolling Forecast and the Forecasted Firm
Order for the ****** of the Rolling Forecast, the Forecasted Firm Order will supersede the Rolling Forecast. Orders for months contained in a Forecasted Firm Order that roll over into the following month’s Forecasted Firm Order will not change
.. RTI shall accept all Forecasted Firm Orders placed by Zimmer and provide a written confirmation of its acceptance within five (5) Business Days after receipt of the Forecasted Firm Order. If any Firm Order (as defined below) or confirmation
conflicts with any term in this Agreement, the term in this Agreement shall govern and control. 
 3.3. Fulfillment of
Orders. RTI shall fulfill in a timely manner all Forecasted Firm Orders for the Implants submitted by Zimmer in accordance with Section 3.2. RTI shall deliver the Implants to Zimmer no later than the delivery date set forth in the
applicable Forecasted Firm Order except to the extent that the aggregate number of Implants ordered for any given month exceeds ******* of the amount of the last Rolling Forecast for such month prior to the submission of the Forecasted Firm Order
for such month, in which case RTI shall deliver the portion of the Forecasted Firm Order that does not exceed ******* of the amount of the last such Rolling Forecast no later than the requested delivery date and will use commercially reasonable
efforts to deliver the excess Implants to Zimmer on the requested delivery date or as soon as commercially practicable thereafter. In the event that RTI is not able to timely deliver an entire Forecasted Firm Order, RTI will deliver as much of the
Forecasted Firm Order as possible and provide immediate written notice to Zimmer of the anticipated supply shortfall by Implant, which notice will specify the cause for the delay and estimated delivery date for the remaining Implants. 

3.4. Additional Orders. In addition to Forecasted Firm Orders, Zimmer may submit additional orders for Implants (each, an
“Additional Order”). RTI agrees to respond in writing to each Additional Order within ten (10) Business Days of receipt, specifying the volumes accepted for production and the estimated date(s) by which said Implants could be
delivered. Zimmer will respond to RTI within five (5) Business Days indicating the types and amount of Implants confirmed for production and delivery. Subject to the availability of tissue, RTI agrees to utilize commercially reasonable efforts
to accept the Additional Order(s) and to timely fulfill all Additional Orders accepted by RTI within the agreed upon delivery date(s). If RTI becomes aware that it will be unable to ship any Implant in response to an Additional Order, RTI will
notify Zimmer in writing within five (5) Business Days after becoming aware of such fact, which notice will specify the cause for the delay or failure to ship and the new delivery date. 

3.5. Initial Stocking Order. On the Effective Date, Zimmer will submit to RTI a binding initial stocking order for Implants
******* and the quantity and mix of Implants to be determined by Zimmer. The Parties agree that the initial stocking order will be shipped and invoiced in partial shipments in accordance with the requirements of this Section 3.5. Unless
approved by RTI ******* and shipment of the full initial stocking order will be completed within six (6) months of the Effective Date. With respect to the initial stocking order, Zimmer will not be required to receive and be invoiced for more
than ******* of Implants in any calendar month and will not be required to take delivery and be invoiced for the full order over less than three (3) consecutive calendar months. Implants ordered in accordance with this Section 3.5 shall
not be counted toward the Minimum Requirements of Section 3.9. Contemporaneously with the execution of this Agreement, the Parties will execute an agreement addressing additional detailed procedures with respect to the transition of the
fulfillment of orders for Implants (the “Transition Services Agreement”) in substantially the form attached to this Agreement as Exhibit D. 

  
 12 

  
 3.6. Orders by
Zimmer Affiliates and Subsidiaries. Notwithstanding any provision to the contrary in this Agreement, the Parties agree that any Affiliate of Zimmer that is appropriately approved or licensed to distribute the Implants as required by Applicable
Laws (including but not limited to Zimmer (Memphis), Zimmer Dental Corp. (Canada), Zimmer Dental GmbH (Germany)) may place Forecasted Firm Orders and/or Additional Orders (collectively, Forecasted Firm Orders and Additional Orders are referred to in
this Agreement as “Firm Orders”) directly with RTI under the terms and conditions of this Agreement, and RTI agrees to ship and invoice such Firm Orders directly to the Zimmer Affiliate placing the Firm Order in accordance with the
terms and conditions of this Agreement. Inherent with the placing of Firm Orders in accordance with this Section 3.6 shall be the obligation of the Zimmer Affiliate(s) to adhere to the Rolling Forecast requirements of Section 3.1. Zimmer
hereby guarantees (i) payment to RTI of invoices for such Firm Orders, and (ii) the Zimmer Affiliate(s)’ adherence to any other applicable provision of this Agreement as necessary to carry out the scope and intent of this
Agreement. 
 3.7. Shipping. RTI shall package, label, store and ship the Implants in compliance with Applicable
Laws (including cGTPs), all applicable Specifications and in accordance with good commercial and industry practice. RTI shall package the Implants suitably for export and appropriately to prevent damage during shipment. The packing slip/delivery
note shall state the implant number, Firm Order number and delivery quantity. The Implants shall be shipped F.O.B. RTI’s facilities in either Neunkirchen, Germany or Alachua, Florida. At Zimmer’s expense, RTI shall ship the Implants to the
Point of Destination designated by Zimmer in the applicable Firm Order. Zimmer shall bear risk of loss during transport and shall be responsible for the costs of freight and insurance to the Point of Destination, unless RTI is unable to fulfill an
entire Firm Order in one shipment or RTI makes multiple shipments for a single Firm Order for any other reason (unless requested by Zimmer or if the order is greater than the ******* of the amount of the most recent Rolling Forecast), in which case
RTI shall bear the shipping costs and expenses for the additional shipments. All shipments shall be made by such carrier(s) as are designated in writing by Zimmer. 
 3.8. Nonconforming Implants. Zimmer, its Marketing Partners and/or the End Users of the Implants, shall have a reasonable right of inspection to verify that the Implants conform to the applicable
Firm Order and the terms of this Agreement. Within fifteen (15) days of initial receipt of a Firm Order, Zimmer, its Marketing Partners and/or the End Users of the Implants, whichever first receives the Implants from RTI, shall inform RTI of
any claim that a shipment contains a shortage of the Implants or that a shipment fails to conform to the applicable Firm Order. If such notice is not provided to RTI within the prescribed time frame, Zimmer shall be deemed to have accepted the
shipment of the Implants for the limited purposes of confirming that the shipment is complete and conforming to the number and type of Implant specified in the Firm Order. With respect to a defect in an Implant that is detected by Zimmer, its
Marketing Partners and/or the End Users of the Implants, Zimmer will notify RTI of its warranty claim pursuant to Section 5.8 of this Agreement. RTI shall bear all costs of return (including freight and insurance) for defective and
non-conforming Implants and shall either replace the defective or nonconforming Implant without charge (including payment of freight and insurance for delivery 

  
 13 

 
of the replacement Implant) or, alternatively, provide a refund or credit to Zimmer for the entire amount paid (including tax, freight and insurance) in connection with the defective or
nonconforming Implant. Nothing in this Section, including the exercise of rights hereunder, shall be construed as a waiver of Zimmer’s indemnification rights, its warranty rights or any other common law or statutory remedies. 

3.9. Minimum Order Volume. The exclusive Distribution rights for the Implants granted under this Agreement shall become
non-exclusive at the option of RTI in the event that Zimmer fails to submit, during the calendar years set forth below, Firm Orders for the Implants with aggregate Fees in the minimum amounts set forth in the following schedule (“Minimum
Requirements”): 
  

			
	 Calendar Year
	  	 Minimum Aggregate Fees

	2011	  	********
	2012	  	********
	2013	  	********
	2014	  	********
	2015	  	********
	2016	  	********
	2017	  	********
	2018	  	********
	2019	  	********
	2020	  	********

 (a) Notice and
Opportunity to Cure. In order to exercise its rights pursuant to this Section, RTI must notify Zimmer in writing of any failure to meet the foregoing Minimum Requirements within thirty (30) days of the end of the particular calendar year
deadline noted above for the achievement of stated Minimum Requirements. Zimmer shall be entitled to an opportunity to cure such failure and retain its exclusive Distribution rights by delivering to RTI, within thirty (30) days of its receipt
of RTI’s notice, (a) one or more Additional Order(s) with aggregate Fees sufficient to satisfy the shortfall in the applicable Minimum Requirements, or (b) a cash payment equal to *******. Any Additional Order(s) submitted by Zimmer
pursuant to (a) above to satisfy the shortfall in Minimum Requirements will be applied to the previous calendar year period (the shortfall period) and not the calendar year in which it is submitted for purposes of determining Zimmer’s
compliance with the Minimum Requirements. 

  
 14 

  
 (b) Loss of
Exclusivity. In the event that Zimmer does not timely cure any failure to achieve the applicable Minimum Requirements for a calendar year after notice is given by RTI in accordance with the time periods required in this Section, then RTI will
have the option to convert Zimmer’s exclusive Distribution rights for the Implants to non-exclusive Distribution rights for the remainder of the Term by notifying Zimmer in writing of its election to do so within thirty (30) days after the
expiration of the applicable cure period. The conversion to non-exclusive will be immediately effective upon expiration of the thirty (30) day notice period. For clarification purposes, RTI’s exclusive remedy for Zimmer’s failure to
meet the Minimum Requirements in this Section is to render the Distribution rights non-exclusive. 
 (c) Carry-forward of
Excess Fees. In the event that the aggregate Fees for Zimmer’s Firm Orders during any calendar year exceed the applicable Minimum Requirement for such calendar year by more than *******, Zimmer shall have the right to carry forward and
apply the excess Fees to the immediately subsequent calendar year for purposes of determining Zimmer’s compliance with the Minimum Requirements for the subsequent calendar year. Excess Fees in one calendar year shall not carry over to any
additional subsequent periods beyond the immediately subsequent calendar year. 
 (d) Exchange Rates. In the case of Fees
paid in Euros for EMEA Implant transfers, the rate of exchange to be used in computing achievement of the Minimum Requirement shall be calculated quarterly at the end of each calendar quarter based on the average of the daily exchange rates
published by the European Central Bank during the applicable calendar quarter. 
 (e)******** 

ARTICLE IV 

PAYMENTS AND FEES 
 4.1. Payments. In partial consideration for the Distribution rights granted to Zimmer under this Agreement, Zimmer shall make the following payments to RTI: (i) a payment of thirteen million
dollars ($13,000,000) for Distribution rights during the Term payable within ten (10) Business Days after the Effective Date of this Agreement (the “Distribution Rights Payment”) and (ii) annual exclusivity maintenance
payments set out in the table below (“Annual Exclusivity Payments”). 
  

			
	 Calendar Year
	  	 Annual Exclusivity Payment

	2011	  	$4,000,000
	2012	  	*******
	2013	  	*******
	2014	  	*******
	2015	  	*******

  
 15 

			
	 Calendar Year
	  	 Annual Exclusivity Payment

	2016	  	*******
	2017	  	*******
	2018	  	*******
	2019	  	*******
	2020	  	*******

 (a) Annual
Exclusivity Payments are payable within ten (10) Business Days following January 1 of each calendar year during the Term, beginning in 2011, for so long as Zimmer maintains the exclusive Distribution rights for Implants granted by RTI
under this Agreement; provided that (i) any Annual Exclusivity Payment that falls due during an Impeding Event shall not be payable until the Impeding Event has been successfully cured or favorably resolved by RTI to the reasonable satisfaction
of Zimmer and the applicable refund has been determined and paid in accordance with this Section 4.1, and (ii) any Annual Exclusivity Payment that falls due after Zimmer has failed to meet the Minimum Requirements shall not be payable
until such failure has been cured by Zimmer. In the event that Zimmer fails to meet the Minimum Requirements and fails to cure the shortfall in accordance with the cure procedures outlined in this Agreement and, as a result, RTI converts
Zimmer’s exclusive Distributions rights under this Agreement to non-exclusive rights, then (x) any Annual Exclusivity Payment made by Zimmer for the then current calendar year, i.e. the calendar year immediately subsequent to the
calendar year in which Zimmer failed to meet the Minimum Requirements, shall be refunded to Zimmer, (y) Zimmer will have no further obligation to pay the Annual Exclusivity Payments to RTI, and (z) Zimmer’s obligation to use RTI as
its sole source provider pursuant to Section 2.3 shall terminate. 
 (b) Upon the occurrence of an Impeding Event
with a duration that is greater than twenty (20) Business Days during the Term of this Agreement, and without limiting the indemnification provisions of this Agreement, Zimmer shall be entitled to a prorated refund of the Distribution Rights
Payment and the current year Annual Exclusivity Payment received by RTI prior to the Impeding Event in an amount equal to the sum of (i) the total amount of the Distribution Rights Payment multiplied by a fraction, the numerator of which is the
number of Business Days from the occurrence of the Impeding Event to the date that it is successfully cured or favorably resolved by RTI to the reasonable satisfaction of Zimmer and the denominator of which is 2500, and (ii) the current year
Annual Exclusivity Payment received by RTI prior to the Impeding Event multiplied by a fraction, the numerator of which is the number of Business Days from the occurrence of the Impeding Event to the date that it is successfully cured or favorably
resolved by RTI to the commercially reasonable satisfaction of Zimmer and the denominator of which is 250. 
 (c)
Notwithstanding the foregoing, and without limiting the indemnification provisions of this Agreement, if the duration of the Impeding Event is greater than sixty (60)

  
 16 

 
Business Days and the Impeding Event is successfully cured or favorably resolved by RTI to the commercially reasonable satisfaction of Zimmer within a commercially reasonable time, not to exceed
six (6) months unless otherwise agreed by the Parties, in lieu of the prorated refund of the Distribution Rights Payment and the current year Annual Exclusivity Payment as set forth above, the Parties agree to negotiate in good faith to
calculate a more significant refund that would take into account the material impact of the Impeding Event on future Distribution of the Implants by Zimmer and the significantly reduced value of the remaining business to Zimmer under the
Distribution rights for the remainder of the Term of this Agreement, which refund shall be no less than three (3) times the amounts that would be calculated using the prorated refund formula in this Section. 

(d) Notwithstanding the foregoing, and without limiting the indemnification provisions of this Agreement, in the event that RTI is
unable to successfully cure or favorably resolve an Impeding Event to the commercially reasonable satisfaction of Zimmer within a commercially reasonable time, not to exceed twelve (12) months unless otherwise agreed by the Parties, failing
which Zimmer shall be entitled to: (i) a refund of the full current year Annual Exclusivity Payment received by RTI prior to the Impeding Event, (ii) a refund of a prorated portion of the Distribution Rights Payments calculated based upon
the occurrence date of the Impeding Event through the end of the Term (the refunds of (i) and (ii) being collectively referred to as the “Refunds”) , and (iii) Zimmer will have no further obligation to make Annual
Exclusivity Payments under this Section for the remainder of the Term of this Agreement. Upon Zimmer’s receipt of the Refunds from RTI pursuant to this Section, Zimmer’s exclusive Distribution Rights for the Implants shall become
non-exclusive. Notwithstanding the foregoing, Zimmer may elect to maintain its exclusive Distribution rights for the remainder of the Term of this Agreement, in which event Zimmer will continue to pay Annual Exclusivity Payments; provided that the
Parties will negotiate in good faith to establish revised lower Annual Exclusivity Payments for the remainder of the Term of this Agreement, which revised Annual Exclusivity Payments shall be no greater than eighty percent (80%) of the amounts
that would be payable for the applicable remaining calendar years as set forth in subsection (a) above. 
 (e) RTI
shall make any refund payment due to Zimmer under subsection (b) or (c) above in cash or immediately available funds within ninety (90) days after resolution of the Impeding Event. Any refund payment due to Zimmer under subsection
(d) above shall be paid by RTI in cash or immediately available funds within fifteen (15) months after the occurrence of the Impeding Event. 
 (f) When reasonably requested by RTI, Zimmer agrees to cooperate with RTI in connection with RTI’s efforts to cure any Impeding Event. Any expenses to be incurred by Zimmer for such
cooperation outside of the ordinary course of its performance under this Agreement will be estimated by Zimmer and submitted to RTI for pre-approval prior to Zimmer incurring any such expense. Approved expenses will be payable to Zimmer by RTI
within thirty (30) days after Zimmer submits documentation of the expenses to RTI for reimbursement. 
 4.2. Fees for
Implants. 
 (a) The initial Fees for Implants ordered by Zimmer under this Agreement are specified in
Exhibit A and those Fees shall be firm through December 31, 2011. 

  
 17 

  
 (b) For the
2012 calendar year and each calendar year thereafter, ******** 
 (c) If the Parties are unable to agree on the Fees
before the commencement of any calendar year, then the Fees for such calendar year shall be equal to the Fees for the previous calendar year increased by *******. 
 (d) Zimmer shall have the right to review and audit RTI’s documentation and records ******** upon thirty (30) days advanced written notice to RTI and at Zimmer’s expense. 

4.3. ******** 
 4.4. Taxes. Zimmer shall pay, in addition to the Fees, any tax imposed on the transfer and/or distribution of the Implants from RTI to Zimmer. 

4.5. Payment Terms. Zimmer shall pay RTI for undisputed Fees invoiced for Implants within thirty (30) days after
Zimmer’s receipt of the applicable RTI invoice. ******* 
 4.6. Material Adverse Market Change. For purposes of this
Section, the Parties agree that a “Material Adverse Market Change” means a change in the End User market for Implants in the Field that is continuing for more than twelve (12) consecutive months during the Term and materially
and adversely affects Zimmer such that the total value of Implants transferred to End Users in the Field by Zimmer decreases year over year by at least ******* because of any combination of End User transfer fees and quantity of Implants
transferred; provided that such decrease in total value of Implants is driven by market forces and not by Zimmer’s failure to perform its obligations under the Agreement in a commercially reasonable manner consistent with past practices. Upon
the occurrence of a Material Adverse Market Change, Zimmer will notify RTI in writing that it wishes to renegotiate certain terms related to the Annual Exclusivity Payments and the Minimum Requirements. For a period of sixty (60) days, the
Parties shall negotiate in good faith to determine adjusted Annual Exclusivity Payments and Minimum Requirements for the remainder of the Term taking such Material Adverse Market Change into consideration. If the Parties cannot reach agreement
within sixty (60) days, Zimmer may, at its discretion, convert its exclusive Distribution rights under this Agreement to non-exclusive Distribution rights by providing written notice of such election to RTI. If Zimmer elects to convert its
Distribution rights under this Agreement to non-exclusive Distribution rights, then within thirty (30) days of its election, Zimmer shall pay to RTI an amount equal to the Annual Exclusivity Payment for calendar year immediately subsequent to
the year of Zimmer’s election, and Zimmer shall have no further obligation to maintain the Minimum Requirements, to pay the Annual Exclusivity Payments or to utilize RTI as its sole source provider pursuant to Section 2.4. 

ARTICLE V 

PROCESSING AND SUPPLY 
 5.1. Capacity. RTI shall maintain sufficient processing capacity (including appropriate processing, storage and distribution facilities and qualified personnel) to meet Zimmer’s forecasted
demand for the Implants. 
 5.2. Inventory. *******  

  
 18 

  
 5.3.
******** 
 5.4. Processing. RTI will recover, screen, Manufacture and release all Implants in accordance with the
Specifications and with all Applicable Laws. RTI shall maintain throughout the Term and for the specified shelf life of the Implant (or for such longer period as may be required by Applicable Laws) accurate and complete records relating to its
procurement, screening, Manufacture and release of the Implants, including all records required under Applicable Laws and Applicable Industry Standards. RTI shall allow Zimmer reasonable access to such records upon request. 

5.5. Implant Modifications. RTI will notify Zimmer in writing in advance of any Specification changes with respect to the
Implants. Any material change in any Specification for the Implants or in RTI’s tissue processing procedures or quality controls which might affect commercial claims or collateral or professional liability claims shall require the prior written
consent of Zimmer, which consent will not be unreasonably delayed or withheld. 
 5.6. Subcontracting. RTI will be
responsible in all respects for Manufacturing and supplying the Implants under this Agreement. RTI will not engage subcontractors to Manufacture the Implants in any respect, without Zimmer’s prior written consent, which consent will not be
unreasonably withheld. RTI shall comply with all Applicable Laws related to suppliers, subcontractors and vendors, and RTI shall require that all of its suppliers, subcontractors and vendors providing services or products in relation to the Implants
are in compliance with all Applicable Laws with regard to such services and products. Notwithstanding Zimmer’s consent to RTI’s use of any subcontracting arrangements, RTI shall remain primarily responsible for performance of its
obligations hereunder, including obligations relating to Implant quality assurance, compliance with Applicable Laws and confidential information, regardless of whether any of RTI’s obligations are undertaken by a subcontractor. 

5.7. Implant Shelf-Life. RTI covenants that all Implants delivered to Zimmer under this Agreement shall have a remaining
shelf-life, as measured from the date of receipt by Zimmer, of at least the minimum shelf life for the applicable Implant set forth on Exhibit A. 
 5.8. Implant Warranty. RTI warrants to Zimmer, its Marketing Partners and the End Users that the Implants, when delivered in accordance with the applicable Firm Order, will (i) conform to the
applicable Specifications, (ii) have been recovered, screened, Manufactured and released in compliance with Applicable Laws (including cGTPs) and Applicable Industry Standards and (iii) be free of defects in design, Manufacture,
fabrication, workmanship, labeling (including Label warnings) and Package Inserts / IFU. The foregoing warranties shall be in effect with respect to each Implant for the labeled shelf life of the Implant. RTI further warrants to Zimmer that the
Implants, when delivered, shall be free and clear of any liens, security interests or encumbrances of any nature whatsoever. RTI DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

  
 19 

  
 ARTICLE VI

 REGULATORY MATTERS 
 6.1. Compliance with Applicable Laws and Industry Standards. Each Party shall comply in all material respects with all Applicable Laws and Applicable Industry Standards that pertain to its
activities under this Agreement and, except as otherwise provided for herein, shall bear the entire cost and expense of such compliance. For avoidance of doubt, and without limiting the generality of the foregoing, each Party shall be responsible
for costs and expenses incurred by such Party in order to maintain quality systems and applicable certifications in compliance with United States quality systems regulations, MDD, AATB and ISO 13485. 

6.2. Development and Regulatory Planning Meetings. RTI and Zimmer will use commercially reasonable efforts to meet quarterly to
discuss regulatory strategies and to agree upon Implant development requirements and priorities. The Parties agree that the fourth quarter meeting in each calendar year will focus on the plans and expectations for new implants in the following
calendar year, including new registrations and the relative priority of such registrations, and any new indications or claims for Implants planned for the following calendar year. The Parties will keep written minutes of each development and
regulatory planning meeting (“DRP Meeting”). 
 6.3. Marketing Approvals. 

(a) RTI represents and warrants to Zimmer that it has applied for and received Marketing Approval for certain Implants in the
countries and jurisdictions specified in Exhibit E-1 and Exhibit E-2 to this Agreement, and that, to the knowledge of RTI, such approvals are in good standing. RTI will be responsible for all costs and expenses relating to the
maintenance of Marketing Approvals specified in Exhibit E-1 and shall have primary responsibility for all communications, submissions and interactions with Regulatory Authorities for the purpose of maintaining such approvals. Zimmer will be
responsible for all costs and expenses relating to the maintenance of Marketing Approvals specified in Exhibit E-2 and shall have primary responsibility for all communications, submissions and interactions with Regulatory Authorities for the
purpose of maintaining such approvals. RTI agrees to cooperate with Zimmer and provide any necessary regulatory assistance as reasonably required by Zimmer in connection with the maintenance of the Marketing Approvals specified on Exhibit E-2
at no cost to Zimmer and agrees that such assistance shall not be counted toward time allotted for assistance to Zimmer in Section 6.4(d). 
 (b) The Parties acknowledge that existing Marketing Approvals may need to be modified or supplemented in certain countries in order to permit the rebranding and Distribution of the Implants by
Zimmer. Zimmer will be responsible for obtaining and maintaining such Marketing Approvals for Zimmer to market and distribute the Implants in the Territory, and for new implants and new indications for Implants as agreed by the Parties. Zimmer
will have primary responsibility for all communications, submissions and interactions with the applicable Regulatory Authorities for the purpose of obtaining and maintaining such modified, supplemented or new Marketing Approvals. 

  
 20 

  
 (c) To the
extent permitted under Applicable Laws, RTI hereby grants to Zimmer the fully paid-up right to use any and all regulatory approvals and clearances related to the Implants in the Territory for applications in the Field owned by or licensed to RTI and
existing as of the Effective Date or obtained during the Term. 
 6.4. Regulatory Assistance from RTI. 

(a) At the request of Zimmer, RTI will provide assistance in creating regulatory master files to develop summary technical
documents (STEDs), or documents in similar format for HCT/Ps, for purposes of obtaining and maintaining Marketing Approvals outside the United States for the distribution of the Implants by Zimmer. RTI will update such files at least annually, or as
otherwise required by applicable Regulatory Laws and to reflect updates to RTI’s quality system. 
 (b) If a
specific Regulatory Authority requires that the tissue processor (or the device manufacturer in the case of Implants that are medical devices) obtain Marketing Approval for the Distribution of the Implants, RTI will use commercially reasonable
efforts to obtain and maintain such Marketing Approval, at Zimmer’s request and expense. In such event, prior to incurring any costs or expenses in connection with such Marketing Approval, RTI shall submit to Zimmer a written budget showing in
reasonable detail the anticipated costs and expenses to be incurred by RTI in connection with obtaining and maintaining such Marketing Approval and will obtain Zimmer’s written approval of such budget before beginning any activities related to
obtaining the Marketing Approval. Zimmer will not be required to reimburse RTI for any costs or expenses in excess of the aggregate budgeted costs and expenses, unless RTI obtains Zimmer’s prior approval for the excess costs and expenses. Any
activity in connection with such Marketing Approval will be subject to prioritization by RTI within its regulatory department but will be completed by RTI within a commercially reasonable timeframe. 

(c) RTI will provide ongoing regulatory consulting support to Zimmer consisting of a monthly conference call to be scheduled as
needed by Zimmer and completion of reasonable follow-up items and issues raised on the monthly call. 
 (d) ********

 6.5. Cooperation. RTI and Zimmer agree to respond to one another regarding regulatory and quality assurance matters in
a timely manner, specifically when such responses are subject to deadlines of Regulatory Authorities. As part of the DRP Meeting in the fourth quarter of each calendar year, the Parties will discuss, prioritize and agree upon a plan for regulatory
activity related to new country registrations, new indications and/or new implant registrations planned for the following calendar year that may require support from RTI so that the appropriate resource plans can be developed. 

6.6. Quality Assurance / Regulatory Affairs Document. Contemporaneously with the execution of this Agreement, the Parties will
execute an agreement addressing additional detailed procedures with respect to quality assurance and regulatory affairs matters relating to the Implants (the “QA/RA Agreement”) in substantially the form attached to this Agreement as
Exhibit F. To the extent that any term in the QA/RA Agreement conflicts with any term of this Agreement, this Agreement shall govern and control. 

  
 21 

  
 6.7. Tissue
Compliance. RTI shall provide tissue to Zimmer under this Agreement that has been recovered, screened and tested for donor eligibility and released for distribution, and processed/handled in accordance with all applicable American Associate of
Tissue Banks standards and FDA requirements (including, but not limited to, 21 C.F.R. Part 1271, Subparts C and D), as revised from time to time. 
 6.8. Registrations and Licenses. RTI and Zimmer shall maintain appropriate federal, state, local and foreign registrations, certifications and licenses as required by Applicable Laws for their
respective duties under this Agreement. 
 6.9. Actions by Regulatory Authorities. RTI shall be responsible to Regulatory
Authorities throughout the Territory as the manufacturer of the Implants. If either Party receives notice of an actual or threatened inspection, investigation, inquiry, import or export ban, implant seizure, enforcement proceeding or similar action
by a Regulatory Authority with respect to any Implant or a Party’s activities in connection with any Implant, it will notify the other Party, within forty-eight (48) hours after its receipt of notice, of the action and will deliver to the
other Party, within a further twenty-four (24) hours, copies of all relevant documents received from the Regulatory Authority. The Parties shall cooperate in response to the action, including providing information and documentation as requested
by the Regulatory Authority (with copies of any such information and documentation to be provided to the other Party). If the action primarily concerns Zimmer’s activities, then Zimmer shall have primary responsibility to respond to the
Regulatory Authority; otherwise, RTI shall have primary responsibility to respond. In either case, upon request of the responding Party, the other Party shall provide consulting advice and assistance with the response. 

6.10. Inspections. Zimmer shall have the right, upon reasonable prior notice to RTI, to inspect and audit RTI’s facilities
and operations for the purpose of verifying RTI’s compliance with its obligations under this Agreement and satisfying all Zimmer quality system requirements, including the right to (a) inspect and take samples of the Implants,
(b) observe Manufacturing and related operations, procedures and methods, (c) review documentation and (d) conduct quality assurance, quality system and regulatory compliance audits. Audits will be scheduled at mutually convenient
times, such scheduling not being subject to unreasonable delay or hindrance. 
 6.11. Labeling. RTI shall have sole
responsibility for obtaining all necessary labeling and for negotiating the language of the Labels and Package Inserts/IFU for the Implants with the Regulatory Authorities in the Territory; however, RTI shall not agree to specific content after the
Effective Date without Zimmer’s prior approval. Zimmer shall bear the cost of all necessary translations for the Labels and Package Inserts/IFU. Prior to incurring any such cost, RTI will submit to Zimmer a written budget showing in reasonable
detail the anticipated costs to be incurred for translations and will obtain Zimmer’s written approval of such budget before incurring such costs. Zimmer will not be required to reimburse RTI for any translation costs in excess of the budget
unless RTI obtains Zimmer’s prior approval for the excess costs. 
 6.12. Third Party Complaints and Reports. The
Parties each shall collect and record Third Party Complaints (and any other events required to be recorded under Applicable Laws) in 

  
 22 

 
accordance with Applicable Laws and their standard procedures and policies in effect from time to time. Each Party shall provide to the other Party reports of such complaints or events within
seventy-two (72) hours after receipt. RTI shall be responsible for investigating all Third Party Complaints and Adverse Events and reporting to Zimmer and the End User, as appropriate. RTI shall be responsible for submitting to the Regulatory
Authorities all required reports and other materials, including annual reports, distribution reports and safety reports. Each Party shall immediately notify the other Party of any material information it learns concerning the safety or efficacy of
the Implant, regardless of whether formal reporting to any Regulatory Authority is required. Zimmer will cooperate with RTI by supplying information and reports as reasonably requested by RTI to assist RTI’s investigation and submissions.

 6.13. Traceability. With respect to the Implants, RTI shall maintain manufacturing and traceability records, including
records by tissue number; and Zimmer shall maintain storage and distribution records by tissue number, as required by Applicable Laws and Applicable Industry Standards. 
 6.14. Field Actions. If the Parties determine to conduct any correction, recall, removal or other Field Action involving an Implant (whether or not required by a Regulatory Authority), RTI shall
have primary responsibility to carry it out in accordance with Regulatory Laws and Zimmer shall provide reasonable support in connection therewith. If it was caused primarily by the negligent (or more culpable) action (including misstatements) or
omission by Zimmer or one of its Affiliates or Marketing Partners, then Zimmer shall bear the related expense; otherwise, RTI shall reimburse Zimmer for Zimmer’s reasonable expenses and either replace the affected Implants free of charge or, at
Zimmer’s election, refund to Zimmer the entire Fee paid for the affected Implants. RTI shall be responsible for any required reporting to Regulatory Authorities. 
 6.15. Survival. The provisions of Sections 6.1, 6.9, 6.12, 6.13 and 6.14 of this Article shall survive any termination or expiration of this Agreement with regard to the Implants distributed
pursuant to this Agreement. 
 ARTICLE VII 
 CONFIDENTIALITY 
 7.1. Confidentiality. In the course of their
activities pursuant to this Agreement, the Parties anticipate that they may disclose Confidential Information to one another and that either Party may, from time to time, be either the disclosing Party or the recipient of Confidential Information.
The Parties wish to protect such Confidential Information in accordance with this Section 7.1. The provisions of this Section shall apply to disclosures furnished to or received by a Party and its agents and representatives (which may
include agents and representatives of its Affiliates and Marketing Partners). Each Party shall advise its agents and representatives of the requirements of this Section and shall be responsible to ensure their compliance with such provisions.

 (a) Definition of Confidential Information. For purposes hereof, “Confidential Information” with
respect to a disclosing Party means all information, in any form or media, concerning the disclosing Party (including patient and donor information) that the disclosing Party furnishes to the recipient, whether furnished before or after the
Effective Date, 

  
 23 

 
and includes all notes, analyses, compilations, studies and other materials, whether prepared by the recipient or others, that contain or reflect such information; provided, however, that
Confidential Information does not include information that (i) is or hereafter becomes generally available to the public other than as a result of a disclosure by the recipient, (ii) was already known to the recipient prior to receipt from
the disclosing Party as evidenced by prior written documents in its possession not subject to an existing confidentiality obligation to the disclosing Party, (iii) is disclosed to the recipient on a non-confidential basis by a person who is not
in default of any confidentiality obligation to the disclosing Party or (iv) is developed by or on behalf of the recipient without reliance on confidential information received under this Agreement. The contents of this Agreement shall be
deemed to be Confidential Information of each Party. 
 (b) Treatment of Confidential Information. The recipient of
Confidential Information will (i) maintain its confidentiality using efforts and precautions at least as great as those it uses and takes to protect its own confidential information and trade secrets, but no less than reasonable care,
(ii) use such Confidential Information solely in connection with the discharge of its obligations under this Agreement and (iii) not disclose such Confidential Information to any person other than those of its agents and representatives
who need to know such Confidential Information in order to accomplish the objectives for which it was disclosed. Notwithstanding the foregoing, the recipient of Confidential Information may disclose it to the extent reasonably necessary to comply
with Applicable Laws or with an order issued by a court or regulatory body with competent jurisdiction; provided that, in connection with such disclosure, the recipient uses commercially reasonable efforts to obtain confidential treatment or an
appropriate protective order, to the extent available, with respect to such Confidential Information. The recipient will provide notice to the disclosing Party immediately upon recipient’s receipt of notification that such disclosure of
Confidential Information is being requested pursuant to Applicable Laws, court or regulatory body order. 
 (c) Return and
Destruction. Upon request of the disclosing Party, the recipient of Confidential Information will promptly redeliver within a commercially reasonable time to the disclosing Party all Confidential Information provided to the recipient in tangible
form, and the recipient will not retain any copies, extracts or other reproductions, in whole or in part, of such Confidential Information. All notes, computer files or other work product prepared by the recipient based upon or incorporating
Confidential Information of the disclosing Party shall be destroyed, and such destruction shall be certified in writing to the disclosing Party by an authorized representative of the recipient who supervised such destruction. Notwithstanding the
foregoing, legal counsel to the recipient shall be permitted to retain in its files one copy of all Confidential Information to evidence the scope of and to enforce the Party’s obligation of confidentiality. 

(d) Term of Obligation. The obligations under this Section shall remain in effect from the Effective Date through the
fifth anniversary of the expiration or termination of this Agreement. 
 (e) Indemnification and Remedies. The
recipient of Confidential Information shall indemnify and hold harmless the disclosing Party from any damage, loss, cost or liability (including reasonable attorneys’ fees) arising out of any breach by the recipient (or its

  
 24 

 
agents or representatives) of its obligations under this Section. In addition to any other remedies available in law or equity, the disclosing Party shall be entitled to temporary and permanent
injunctive relief in the event of a breach (or threatened breach) under this Section. 
 (f) Prior Agreements. The
provisions of this Section shall supersede and replace any prior agreements between the Parties relating to Confidential Information covered hereby. 
 7.2. Publicity. Neither RTI nor Zimmer shall issue any press release or otherwise publicize the subject matter of this Agreement without the prior written approval of the other Party, except to the
extent that such press release or other public announcement is required by the rules governing a securities exchange on which the releasing Party’s stock is listed, by law in the opinion of legal counsel to the releasing Party, or the substance
thereof has been previously reviewed and released by the other Party or is in the public domain through no fault of the releasing Party. In the event of a required press release or other public announcement, the releasing Party shall provide the
other Party with a copy of the proposed text prior to such announcement. The Parties agree that if either Party is required to file this Agreement with any Governmental Authority, the releasing Party shall redact the financial terms of this
Agreement to the extent possible in order to keep the financial terms of this Agreement confidential. 
 ARTICLE VIII

 INTELLECTUAL PROPERTY 
 8.1. IP Representations. RTI hereby represents and warrants to, and covenants with, Zimmer as follows: 
 (a) RTI owns or holds valid and enforceable rights to use and license (to the extent a license is required), without infringing, misappropriating or violating the rights of any Person, any
Intellectual Property that is necessary for (i) RTI to Manufacture and supply the Implants, (ii) Zimmer to Distribute the Implants as contemplated by this Agreement and (iii) RTI to grant to Zimmer and its Affiliates and Marketing
Partners the Distribution rights under this Agreement. 
 (b) RTI has not previously granted any license, covenant not to
sue or other right currently in effect that would be inconsistent with or conflict with the grant of the Distribution rights under this Agreement. 
 (c) No Person has asserted a claim, suit, proceeding, action or demand (a “Claim”) with respect to any of the RTI IP, which Claim (i) challenges the validity of RTI’s
interest in the RTI IP, (ii) alleges that RTI’s use or practice of the RTI IP infringes, misappropriates or violates the rights of any Person or (iii) seeks to enjoin or restrain RTI’s use or practice of the RTI IP in any manner
that would interfere with the transactions contemplated by this Agreement. RTI has no knowledge that any Person intends to assert such a Claim. 
 8.2. Trademarks. Zimmer and its Affiliates and Marketing Partners shall have the right to use RTI’s Trademarks associated with the Implants (including but not limited to Tutoplast® and CancelleTM SP) as required by applicable Regulatory laws or as otherwise necessary in connection with
Zimmer’s distribution of the Implants. Zimmer and its Affiliates and 

  
 25 

 
Marketing Partners shall comply with the reasonable quality control instructions of RTI as to the form and manner in which such Trademarks shall be used. Any Trademarks developed by Zimmer for
the Implant shall be owned exclusively by Zimmer; provided, however, that if Zimmer determines that it is necessary or prudent for regulatory purposes to register any of its Trademarks in the name of RTI in any jurisdiction, then Zimmer shall be
permitted to assign such Trademarks to RTI and RTI shall file any registration applications or other comparable filings for such Trademarks as requested by Zimmer at Zimmer’s expense. Upon the expiration or termination of this Agreement, RTI
hereby assigns all right, title and interest in and to any such Trademarks back to Zimmer, and RTI shall take such other actions as may be reasonably requested by Zimmer to vest and protect its right, title and interest in and to such Trademarks.
Other than as expressly provided herein, no Party shall acquire or have any right to use the name or Trademarks of the other Party without its prior written consent. Zimmer hereby grants such reciprocal rights in its Trademarks to RTI as reasonably
necessary for RTI to carry out the scope and intent of its obligations pursuant to this Agreement. 
 8.3. Commercialization
License. During the Term of this Agreement, RTI hereby grants to Zimmer a royalty-free license and right, with the right to sublicense to its Affiliates and Marketing Partners, under the RTI IP and all improvements and future developments with
respect thereto, to use, Distribute and import/export the Implants in the Field throughout the Territory (the “Commercialization License”). The Commercialization License shall be exclusive for the Territory, subject to
Section 3.4(b). The Commercialization License shall be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, a license to rights to “intellectual property” as defined therein. Zimmer, as licensee
of such rights, shall have the rights and elections with respect thereto as specified in the United States Bankruptcy Code. This Agreement shall be deemed to be an “agreement supplemental to” the Commercialization License for purposes
of Section 365(n) of the United States Bankruptcy Code. 
 ARTICLE IX 

REPRESENTATIONS AND WARRANTIES 
 9.1. Each Party hereby represents and warrants to, and covenants with, the other Party that: 
 (a) Due Organization, Good Standing and Power. It is a corporation or other entity duly organized, validly existing and, if relevant in its jurisdiction of organization, in good standing under the
laws of its jurisdiction of organization and has the power and authority to own, lease and operate its assets and to conduct the business now being conducted by it. It has all requisite power and authority to enter into this Agreement and to perform
its obligations hereunder. 
 (b) Authorization and Validity of Agreement. The execution, delivery and performance by it
of this Agreement and the consummation by it of the transactions contemplated hereby have been duly authorized and approved by all necessary corporate or equivalent action on its part. This Agreement has been duly executed and delivered by it and
constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws relating to or affecting
creditors’ rights generally and by general equity principles. 

  
 26 

  
 (c) Absence of
Conflicts. The execution, delivery and performance by it of this Agreement and the consummation by it of the transactions contemplated hereby do not and will not: (i) violate any Applicable Laws; (ii) conflict with, or result in the
breach of any provision of, its certificate or articles of incorporation, bylaws or equivalent organizational documents; (iii) result in the creation of any lien or encumbrance of any nature upon any property being transferred or licensed by it
pursuant to this Agreement or (iv) violate, conflict with, result in the breach or termination of, or constitute a default under (or event which, with notice, lapse of time or both, would constitute a default under), any permit, contract or
agreement to which it is a party or by which any of its properties or businesses are bound. 
 (d) Consents. No
authorization, consent or approval of, or notice to or filing with, any Governmental Authority is required for the execution, delivery and performance by it of this Agreement, other than regulatory approvals that have not been obtained prior to the
Effective Date. 
 ARTICLE X 
 ******** 

  
 27 

  
 ARTICLE XI

 INDEMNIFICATION AND INSURANCE 
 11.1. Indemnification by RTI. 
 (a) Scope. RTI shall indemnify and
hold harmless Zimmer and its Affiliates and Marketing Partners and their respective shareholders, directors, officers, employees and agents from and against any and all liabilities, damages, losses, penalties, fines, costs and expenses, including
reasonable attorneys’ fees and litigation costs, paid or incurred by them in connection with any Claim based upon or arising from: (i) any bodily injury, death or property damage resulting from any defect in the design, material,
Manufacture, fabrication, workmanship, labeling (including Label warnings) and Package Inserts / IFU of the Implants or from the failure of such Implant to conform to the applicable Specifications therefor (a “Professional Liability
Claim”); (ii) any infringement or violation of a Third-Party’s Intellectual Property as a result of the use, Manufacture or Distribution of the Implants (except to the extent that any such alleged infringement or violation is
attributed to Zimmer marks; (iii) any facts or circumstances that would constitute a breach by RTI of any of its representations, warranties or obligations under this Agreement; (iv) any violation by RTI of Applicable Laws or (v) any
negligent or more culpable act (including misstatements) or omission of RTI or its Affiliates or subcontractors or any of their respective employees or agents relating to the activities subject to this Agreement. 

(b) Defense. Zimmer shall give RTI prompt written notice of any Claim with respect to which RTI’s indemnification obligations
may apply, but any delay or failure of such notice shall not excuse RTI’s indemnification obligations except to the extent that RTI’s legal position is prejudiced thereby. RTI shall have the right to assume and control the defense and
settlement of any such Claim; except that Zimmer shall have the right to assume and control, at RTI’s expense, the defense and settlement of any such Claim if: (i) Zimmer reasonably determines that there is a conflict of interest between
Zimmer and RTI with respect to such Claim; (ii) RTI fails to employ counsel reasonably satisfactory to Zimmer to represent Zimmer within a reasonable time after RTI’s receipt of notice of the Claim or (iii) in the reasonable opinion
of counsel to Zimmer, the Claim could result in Zimmer becoming subject to injunctive or other non-monetary relief that could have a material adverse effect on Zimmer’s ongoing business. The Party not controlling the defense shall have the
right to participate in the Claim at its own expense, but in any event shall cooperate with the controlling Party in the investigation and defense of the Claim. 
 (c) Settlement. If RTI is entitled to, and does, assume and control the defense and settlement of any Claim with respect to which its indemnification obligations apply, then RTI shall not settle
such Claim without Zimmer’s prior written consent (which consent shall not be unreasonably withheld or delayed), unless (i) the sole relief provided in such settlement is monetary in nature and shall be paid in full by RTI and
(ii) such settlement does not include any finding or admission of a violation by Zimmer of any Applicable Laws or Third-Party’s rights. Whenever Zimmer assumes and controls the defense and settlement of a Claim with respect to

  
 28 

 
which RTI’s indemnification obligations apply, RTI shall not be liable for any settlement thereof effected by Zimmer unless Zimmer shall have obtained RTI’s prior written consent to the
proposed settlement (which consent shall not be unreasonably withheld or delayed). 
 (d) Insurance. RTI shall maintain,
from the Effective Date through the fifth anniversary of the expiration date of the Term, a policy of insurance for Professional Liability Claims. Such policy shall (i) have a per occurrence limit of at least ******* and an annual
aggregate limit of at least *******, (ii) name Zimmer as an additional insured and (iii) provide for at least thirty (30) days’ advance written notice to Zimmer of cancellation or material change in coverage. RTI shall provide
evidence of such coverage to Zimmer promptly following execution of this Agreement and annually thereafter. If RTI breaches its obligation to maintain insurance, (x) Zimmer shall have the right to obtain coverage as required on RTI’s
behalf and at RTI’s expense, (y) Zimmer shall have the right to set-off the cost of such coverage against any payment owed to RTI for Implants supplied under this Agreement and (z) RTI shall indemnify Zimmer from and against all costs
and expenses associated with obtaining such coverage. 
 11.2. Indemnification by Zimmer. 

(a) Scope. Zimmer shall indemnify and hold harmless RTI and its Affiliates and their respective shareholders, directors, officers,
employees and agents from and against any and all liabilities, damages, losses, penalties, fines, costs and expenses, including reasonable attorneys’ fees and litigation costs, paid or incurred by them in connection with any Claim based upon or
arising from: (i) any facts or circumstances that would constitute a breach by Zimmer of any of its representations, warranties or obligations under this Agreement; (ii) any violation by Zimmer of Applicable Laws, (iii) any
infringement or violation of a Third Party’s Intellectual Property as a result of the use, Manufacture or Distribution of the Implants to the extent that such alleged infringement or violation is attributed to Zimmer marks; or (iv) any
negligent or more culpable act (including misstatements) or omission of Zimmer or its Affiliates or Marketing Partners or any of their respective employees or agents relating to the activities subject to this Agreement. 

(b) Defense. RTI shall give Zimmer prompt written notice of any Claim with respect to which Zimmer’s indemnification
obligations may apply, but any delay or failure of such notice shall not excuse Zimmer’s indemnification obligations except to the extent that Zimmer’s legal position is prejudiced thereby. Zimmer shall have the right to assume and control
the defense and settlement of any such Claim; except that RTI shall have the right to assume and control, at Zimmer’s expense, the defense and settlement of any such Claim if: (i) RTI reasonably determines that there is a conflict of
interest between Zimmer and RTI with respect to such Claim; (ii) Zimmer fails to employ counsel reasonably satisfactory to RTI to represent RTI within a reasonable time after Zimmer’s receipt of notice of the Claim or (iii) in the
reasonable opinion of counsel to RTI, the Claim could result in RTI becoming subject to injunctive or other non-monetary relief that could have a material adverse effect on RTI’s ongoing business. The Party not controlling the defense shall
have the right to participate in the Claim at its own expense, but in any event shall cooperate with the controlling Party in the investigation and defense of the Claim. 

  
 29 

  
 (c) Settlement.
If Zimmer is entitled to, and does, assume and control the defense and settlement of any Claim with respect to which its indemnification obligations apply, then Zimmer shall not settle such Claim without RTI’s prior written consent (which
consent shall not be unreasonably withheld or delayed), unless (i) the sole relief provided in such settlement is monetary in nature and shall be paid in full by Zimmer and (ii) such settlement does not include any finding or admission of
a violation by RTI of any Applicable Laws or Third-Party’s rights. Whenever RTI assumes and controls the defense and settlement of a Claim with respect to which Zimmer’s indemnification obligations apply, Zimmer shall not be liable for any
settlement thereof effected by RTI unless RTI shall have obtained Zimmer’s prior written consent to the proposed settlement (which consent shall not be unreasonably withheld or delayed). 

11.3. Combined Obligations. To the extent that Zimmer and RTI have indemnification obligations to one another in connection with a
single Claim, Zimmer and RTI shall contribute to the aggregate damages arising from such Claim in such proportion as is appropriate to reflect their relative responsibilities for such damages, as well as any other relevant equitable considerations.
The amount paid or payable by Zimmer or RTI for purposes of apportioning the aggregate damages shall be deemed to include all reasonable legal fees and expenses incurred by such Party in connection with investigating, preparing for or defending
against such Claim. 
 11.4. Survival; Waiver. The provisions of this Article shall survive any termination or
expiration of this Agreement. Any waiver by an indemnified Party of its rights under this Article must be set forth expressly and in writing in order to be effective. 
 ARTICLE XII 
 TERM AND TERMINATION 

12.1. Term. This Agreement shall become effective on the Effective Date and shall continue in effect until December 31, 2020
(the “Initial Term”). The Initial Term will be renewed automatically thereafter for successive two-year periods provided that Zimmer gives RTI written notice of its intent to renew the Agreement at least 365 days prior to the
expiration of the Initial Term or the applicable renewal term. The Parties agree that the Minimum Requirements for each renewal term will be equal to ******** of the Minimum Requirements for the final calendar year of the Initial Term or the prior
renewal term, as applicable, and that the Annual Exclusivity Payment for the renewal term will be equal to ******** of the Annual Exclusivity Payment for the final calendar year of the Initial Term or the prior renewal term, as applicable. This
Agreement may be terminated before expiration of the Initial Term or any renewal term only by agreement of the Parties or in accordance with Section 12.2. The period from the Effective Date through the date of expiration or termination of this
Agreement shall be referred to as the “Term.” 
 12.2. Termination. 

(a) Dissolution or Insolvency Event. If a Party is dissolved under applicable corporate law or becomes subject to an Insolvency
Event, the other Party may terminate this Agreement by delivering written notice of its decision to do so within six (6) months after actual knowledge of the dissolution or the Insolvency Event. 

  
 30 

  
 (b) Default. If
either Party believes the other is in default of any of its material obligations under this Agreement, it may give notice to the other Party describing the default with reasonable specificity. The defaulting Party shall have sixty (60) days in
which to remedy such default. Such cure period shall be extended in the case of a default not reasonably capable of being remedied in such 60-day period so long as the defaulting Party uses diligent efforts to remedy such default and is pursuing a
course of action that, if successful, will effect such a remedy. If such alleged default is not remedied in the time period set forth above, the Party alleging default shall refer the matter to senior executive officers of each Party, who shall meet
and confer within fifteen (15) days after notice from the non-defaulting Party of its desire for such a meeting. If the Parties are unable to resolve any dispute in such meeting, the non-defaulting Party may terminate this Agreement upon
delivery to the defaulting Party of a written notice of termination at any time within six (6) months after the meeting but before such default is remedied. The non-defaulting Party’s right to terminate this Agreement shall not be
construed as an exclusive remedy. 
 (c) Change of Control. If a Party is subject to a Change of Control and the
acquiring Person is, in the other Party’s reasonable judgment, a direct competitor to the other Party, the Party that is not subject to the Change of Control may terminate this Agreement effective immediately upon delivery of written notice of
termination within six (6) months after consummation of the Change of Control. 
 (d) Force Majeure. Either Party
may terminate this Agreement in accordance with the terms of Section 13.2. 
 12.3. Consequences of Termination.

 (a) General. Termination or expiration of this Agreement shall not relieve any Party of any obligations that are
expressly indicated to survive termination or expiration and, accordingly, any provision of this Agreement required for the interpretation or enforcement of any such obligation will survive the expiration or termination of this Agreement.
Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. 

(b) Inventory. Upon the expiration or termination of this Agreement, (i) at Zimmer’s request, RTI shall continue to
process and deliver to Zimmer all Implants that are the subject of a Firm Order from Zimmer as of the date of expiration or termination and (ii) Zimmer shall be permitted to distribute any remaining inventory of the Implants until depleted,
including any Implants delivered pursuant to clause (i) above (and for such purpose Zimmer Distribution’s rights under this Agreement shall continue in effect). 
 (c) No Additional Payments Due. In the event that Zimmer elects to terminate this Agreement pursuant to Section 12.2, Zimmer shall have no further obligation to make payments under this
Agreement other than outstanding payments for invoiced Implants, or Implants subject to a Firm Order as stated in Section 12.3(b). 

  
 31 

  
 ARTICLE XIII

 MISCELLANEOUS 
 13.1. Agency. The Parties are independent contractors. No employee or agent of one Party is, nor shall be deemed to be, based on performance of this Agreement, an employee, agent, partner or legal
representative of the other Party for any purpose. Neither Party shall have the right, power or authority to enter into any contracts in the name of, or on behalf of, the other Party, nor shall either Party have the right, power or authority to
pledge the credit of the other Party in any way or hold itself out as having the authority to do so. 
 13.2. Force
Majeure. If the performance of any obligation under this Agreement is prevented, restricted or interfered with by reason of war, revolution, civil commotion, acts of terrorism, blockade, embargo, strikes, government acts (generally prohibiting
or limiting allograft or xenograft tissue transfer and not directed specifically at RTI or the Implants), natural disasters or similar event which is beyond the reasonable control of the Party affected, then the Party so affected shall, upon giving
prior written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, or interference, provided that the Party so affected shall use commercially reasonable efforts to avoid or remove such causes of
nonperformance, and shall continue performance hereunder with reasonable dispatch whenever such causes are removed. If such conditions inhibiting complete performance shall continue in excess of ninety (90) days, the Parties shall attempt to
arrive at a mutually acceptable compromise within the spirit and intent of this Agreement. If the Parties fail to reach a mutually acceptable compromise within ninety (90) days following the initial attempt to negotiate the same, then the Party
who is not affected by the force majeure event shall have the option, by delivery of written notice of termination to the affected Party, to terminate this Agreement. The Parties agree that issues or problems with tissue supply will not constitute a
force majeure event. 
 13.3. Non-Solicitation. During the Term of this Agreement and for a period of one (1) year
thereafter (the “Non-Solicitation Period”), Zimmer will not, directly or indirectly, actively solicit for employment or employ any employee of RTI involved in RTI’s performance of this Agreement, without the prior
written consent of RTI. Notwithstanding the foregoing, nothing in this Section will limit or prohibit Zimmer from its ability to make generalized searches for employees by the use of advertisements in the media (including trade media) or by engaging
search firms to engage in searches that are not specifically directed by Zimmer to target such RTI employees. In the event that a RTI employee involved in RTI’s performance of this Agreement voluntarily leaves his or her position at RTI during
the Non-Solicitation Period, Zimmer will not employ such former RTI employee until at least six (6) months after the end of his or her employment with RTI. If a RTI employee involved in RTI’s performance of this Agreement is terminated
involuntarily by RTI during the Non-Solicitation Period, Zimmer may employ such former RTI employee immediately. 
 13.4.
Entire Agreement; Amendments. This Agreement, together with the QA/RA Agreement and the Transition Services Agreement, constitutes the entire agreement between the Parties hereto concerning its subject matter and supersedes all previous
negotiations, agreements and commitments with respect thereto. This Agreement specifically supersedes and replaces the U.S. Agreement, the Xenograft Agreement, the Development Agreement, the Canada Agreement and the International Agreement
previously entered into by the Parties and/or their Affiliates with 

  
 32 

 
regard to the distribution of certain Implants. This Agreement does not supersede the DBM Agreement, which shall remain in full force and effect in accordance with its terms. This Agreement shall
not be released, discharged, amended or modified in any manner except by a written instrument signed by duly authorized officers or representatives of each of the Parties hereto. 

13.5. Governing Law. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of
Illinois, without regard to its choice of law rules. The Parties agree that any legal action relating to this Agreement shall be commenced and maintained before any appropriate state court of record in Cook County, Illinois, or, if necessary, the
United States District Court for the Northern District of Illinois, and the Parties hereby submit to the jurisdiction of such courts and waive any right to challenge or otherwise raise questions of personal jurisdiction or venue in any action
commenced or maintained in such courts. 
 13.6. Partial Illegality. If any provision of this Agreement, or the
application thereof to any Party or circumstances, shall be declared void, illegal or unenforceable, the remainder of this Agreement shall be valid and enforceable to the extent permitted by Applicable Laws. In such event, the Parties shall use
their best efforts to replace the invalid or unenforceable provision by a provision that, to the extent permitted by Applicable Laws, achieves the purposes intended under the invalid or unenforceable provision. Any deviation by either Party from the
terms and provisions of this Agreement in order to comply with Applicable Laws shall not be considered a breach of this Agreement. 
 13.7. Waiver of Compliance. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees, except by an instrument in writing expressly
waiving such provision and signed by a duly authorized officer of the waiving Party, which waiver shall be effective only with respect to the specific obligation and instance described therein. 

13.8. Notices. All notices and other communications in connection with this Agreement shall be in writing and shall be sent to the
respective Parties at the following addresses, or to such other addresses as may be designated by the Parties in writing from time to time in accordance with this Section, by registered or certified mail, postage prepaid, or by express courier
service, service fee prepaid, or by facsimile with a hard copy to follow via mail or express courier service in accordance with this Section. 
  

	         TO RTI: 
	RTI Biologics, Inc. 

	 	11621 Research Circle 

	 	Alachua, FL 32615 

	 	Attn: Chief Financial Officer 

	 	Fax No.: (386) 462-3821 

  
 33 

  

	         With copy to: 
	Corporate Counsel 

	 	RTI Biologics, Inc. 

	 	11621 Research Circle 

	 	Alachua, FL 32615 

	 	Facsimile: (386) 418-5157 

  

	         TO ZIMMER: 
	Zimmer Dental, Inc. 

	 	1900 Aston Avenue 

	 	Carlsbad, California 92008 

	 	Attn: President 

	 	Fax No.: (760) 431-9753 

  

	         With a copy to: 
	Zimmer Legal Department 

	 	345 East Main Street 

	 	Warsaw, IN 46580 

	 	Attn: Assistant General Counsel 

	 	Fax No.: (574) 371-8591 

  

	 	Zimmer Dental, Inc. 

	 	1900 Aston Avenue 

	 	Carlsbad, California 92008 

	 	Attn: Division General Counsel 

	 	Fax No.: (760) 431-9753 

 All notices shall be deemed
given and received (i) if delivered by hand, immediately, (ii) if sent by mail, three (3) Business Days after posting, (iii) if delivered by express courier service, the next Business Day in the jurisdiction of the recipient or
(iv) if sent by fax, at the time shown in the confirmed electronic receipt, or on the first Business day thereafter if the notice is not sent on a Business Day. 
 13.9. Counterparts and Facsimile/Electronic. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and
the same instrument. A manual signature on this Agreement or any document executed in connection with this Agreement, the image of which is transmitted electronically (including facsimile or e-mail), shall constitute an original signature for
purposes of this Agreement. 
 13.10. Limitation on Liability. Except with respect to the Parties’ indemnification
obligations, neither Party shall be liable to the other for indirect, incidental, consequential, punitive or special damages, including but not limited to lost profits, arising from or relating to any breach of this Agreement, regardless of any
notice of the possibility of such damages. 
 13.11. Further Actions. Each Party agrees, subsequent to the execution and
delivery of this Agreement and without any additional consideration, to execute, acknowledge and deliver such further documents and instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and
intent of this Agreement. 

  
 34 

  
 13.12.
Assignment. Except as otherwise provided herein, neither Party shall have the right to assign any of its rights or obligations under this Agreement without the prior written consent of the other Party. Without limiting the termination rights set
forth in Section 12.2(c), either Party, without any need for consent from the other Party, may assign this Agreement or any of its rights and/or obligations hereunder to an Affiliate or in connection with a merger or other business combination
or the sale of substantially all of the assets of such assigning Party; provided, however, that such assignment shall not relieve the assigning Party of its obligations hereunder. If and to the extent that a Party assigns any of its rights and/or
obligations hereunder in accordance with this Section, then this Agreement shall be binding upon the assignee to the same extent as if it were a Party hereto and each reference herein to the name of the assigning Party shall be deemed to include the
assignee. Any assignment not in accordance with this Section shall be void. 
 13.13. Jointly Prepared. This Agreement
has been prepared jointly and shall not be strictly construed against either Party. 
 13.14. Third-Party Rights. Except
as expressly provided herein, this Agreement is not intended to confer any benefits upon, or create any rights in favor of, any Person other than the Parties and, where expressly provided, their Affiliates and Marketing Partners and the Persons
entitled to indemnification. 
 13.15. Expenses. Except as otherwise expressly provided in this Agreement, each Party
shall be responsible for its own expenses incurred in connection with this Agreement and the transactions contemplated hereby. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK; 
 SIGNATURES APPEAR ON FOLLOWING PAGE]

  
 35 

  
 IN WITNESS WHEREOF,
each Party has caused this Agreement to be executed by its respective duly authorized representative as of the Effective Date. 
  

			
	RTI BIOLOGICS, INC.

			
		
	By:	 	 /s/ Robert P. Jordheim

			
		
	Name:	 	 Robert P. Jordheim

			
		
	Title:	 	 Executive Vice President / CFO

	
	ZIMMER DENTAL, INC.

			
		
	By:	 	 /s/ David C. Dvorak

			
		
	Name:	 	 David C. Dvorak

			
		
	Title:	 	 President and CEO

  
 36 

  
 EXHIBIT A

 IMPLANTS 
  

											
	 Part
 Numbers:
 US, LA,

APR, CAN
	  	
Brand / Product Description
	  	 Transfer Fee

US/LA/APR/CN
	  	 Lead time
Calendar
Days
	  	 Label
Shelf

Life
	  	 Minimum
Shelf Life

		  	Bovine Membranes	  		  		  		  	
	 7778

97004
	  	 CopiOs Pericardium Membrane 30x40mm
	  	*******	  	*******	  	*******	  	*******
						
	 7777

97003
	  	 CopiOs Pericardium Membrane 20x30mm
	  	*******	  	*******	  	*******	  	*******
						
	 7776

97002
	  	 CopiOs Pericardium Membrane 15x20mm
	  	*******	  	*******	  	*******	  	*******
						
		  	Human Bone Allograft	  		  		  		  	
	 8210R

8210z
 67210
 68210
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 0,5cc
	  	*******	  	*******	  	*******	  	*******
						
	 8211R

8211z
 67211
 68211
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 1cc
	  	*******	  	*******	  	*******	  	*******
						
	 8209R

8209Z
 67209
 68209
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 2cc
	  	*******	  	*******	  	*******	  	*******
						
	 8212R

8212Z
 67212
 68212
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 0,5cc
	  	*******	  	*******	  	*******	  	*******
						
	 8213R

8213Z
 67213
 68213
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 1cc
	  	*******	  	*******	  	*******	  	*******
						
	 8214R

8214Z
 67214
 68214
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 2cc
	  	*******	  	*******	  	*******	  	*******
						
	 67215

68215
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 3cc
	  	*******	  	*******	  	*******	  	*******

 EXHIBIT A - Continued 
  

											
	 Part
 Numbers:
 US, LA,

APR, CAN
	  	
Brand / Product Description
	  	 Transfer Fee

US/LA/APR/CN
	  	 Lead time
Calendar
Days
	  	 Label
Shelf

Life
	  	 Minimum
Shelf Life

	 67216

68216
	  	 PUROS CANCELLOUS Particulate ø 2-4mm, 3cc
	  	*******	  	*******	  	*******	  	*******
						
	 8276R

8276Z
 67276
 68276
	  	 PUROS Cortical Particulate ø 1-2mm, 2cc
	  	*******	  	*******	  	*******	  	*******
						
	 8275R

8275Z
 67275
 68275
	  	 PUROS Cortical Particulate ø 1-2mm, 1cc
	  	*******	  	*******	  	*******	  	*******
						
	 8274R

8274Z
 67274
 68274
	  	 PUROS Cortical Particulate ø 1-2mm, 0,5cc
	  	*******	  	*******	  	*******	  	*******
						
	 8273R

8273Z
 67273
 68273
	  	 PUROS Cortical Particulate ø 0,25-1mm, 2cc
	  	*******	  	*******	  	*******	  	*******
						
	 8272R

8272Z
 67272
 68272
	  	 PUROS Cortical Particulate ø 0,25-1mm, 1cc
	  	*******	  	*******	  	*******	  	*******
						
	 8271R

8271Z
 67271
 68271
	  	 PUROS Cortical Particulate ø 0,25-1mm, 0,5cc
	  	*******	  	*******	  	*******	  	*******
						
	 67220
	  	 PUROS Block 15x10x9mm P-Block Design
	  	*******	  	*******	  	*******	  	*******
	 68737
	  	 Tutoplast Spongiosa block P 15x10x9mm
	  	*******	  	*******	  	*******	  	*******
						
	 68220

8220Z
 8220R
	  	 Puros Block J-Block Design 10mm
	  	*******	  	*******	  	*******	  	*******
						
	 68221

8221Z
 8221R
	  	 Puros Block J-Block Design 15mm
	  	*******	  	*******	  	*******	  	*******
						
	 67221
	  	 PUROS Corticospongiosa Block 15x15x9mm P-Block
	  	*******	  	*******	  	*******	  	*******
	 68736
	  	 Tutoplast Spongiosa Block-P 15x15x9mm
	  	*******	  	*******	  	*******	  	*******

 EXHIBIT A - Continued 
  

											
	 Part
 Numbers:
 US, LA,

APR, CAN
	  	
Brand / Product Description
	  	 Transfer Fee

US/LA/APR/CN
	  	 Lead time
Calendar
Days
	  	 Label
Shelf

Life
	  	 Minimum
Shelf Life

		  	Allograft Membrane	  		  		  		  	
	 8790R

8790Z
 68790
	  	 Puros Dermis Dental Membrane 0.8-1.8mm, 10 x 20 mm
	  	******	  	******	  	******	  	******
						
	 8791R

8791Z
 68791
	  	 Puros Dermis Dental Membrane 0.8-1.8mm, 10 x 40 mm
	  	******	  	******	  	******	  	******
						
	 8792R

8792Z
 68792
	  	 Puros Dermis Dental Membrane, 0.8-1.8mm, 20 x 40 mm
	  	******	  	******	  	******	  	******
						
	 8793R

8793Z
 68793
	  	 Puros Dermis Dental Membrane 0.8-1.8mm, 10 x 10 mm
	  	******	  	******	  	******	  	******
						
	 8794R

8794Z
 68794
	  	 Puros Dermis Allograft 0.3-0.8 mm 10 x 10 mm
	  	******	  	******	  	******	  	******
						
	 8795R

8795Z
 68795
	  	 Puros Dermis Allograft 0.3-0.8 mm 10 x 20 mm
	  	******	  	******	  	******	  	******
						
	 8796R

8796Z
 68796
	  	 Puros Dermis Allograft 0.3-0.8 mm 10 x 40 mm
	  	******	  	******	  	******	  	******
						
	 8797R

8797Z
 68797
	  	 Puros Dermis Allograft 0.3-0.8 mm 20 x 40 mm
	  	******	  	******	  	******	  	******
		  	Allograft Pericardium	  		  		  		  	
	 8770R

8770Z
 68770
	  	 15 X 20 Puros Pericardium
	  	******	  	******	  	******	  	******
						
	 8771R

8771Z
 68771
	  	 20 X 30 Puros Pericardium
	  	******	  	******	  	******	  	******
						
	 8772R

8772Z
 68772
	  	 30 X 40 Puros Pericardium
	  	******	  	******	  	******	  	******

 EXHIBIT A - Continued 
  

											
	 Part
 Numbers:
 US, LA,

APR, CAN
	  	
Brand / Product Description
	  	 Transfer Fee

US/LA/APR/CN
	  	 Lead time
Calendar
Days
	  	 Label
Shelf

Life
	  	 Minimum
Shelf Life

		  	Bovine Bone	  		  		  		  	
	 90101
	  	 Tutodent Block 10x10x20
	  	******	  	******	  	******	  	******
	 97101
	  	 CopiOs Block 10x10x20mm
	  	******	  	******	  	******	  	******
						
	 90280
	  	 Tutodent CS - Block 15mm x 10mm x 5,5mm
	  	******	  	******	  	******	  	******
	 97280
	  	 CopiOs CS Block 15x10x5.5mm
	  	******	  	******	  	******	  	******
						
	 90282
	  	 Tutodent CS - Block 15mm x 15mm x 5,5mm
	  	******	  	******	  	******	  	******
	 97282
	  	 CopiOs CS Block 15x15x5.5
	  	******	  	******	  	******	  	******
						
	 90200
	  	 Tutodent .5cc - .25-1mm
	  	******	  	******	  	******	  	******
	 97200
	  	 CopiOs Cancellous .5cc - .25-1mm
	  	******	  	******	  	******	  	******
						
	 90201
	  	 Tutodent 1.0cc - .25-1mm
	  	******	  	******	  	******	  	******
	 97201
	  	 CopiOs Cancellous 1.0cc - .25-1mm
	  	******	  	******	  	******	  	******
						
	 90202
	  	 Tutodent 2.0cc - .25 - 1mm
	  	******	  	******	  	******	  	******
	 97202
	  	 CopiOs Cancellous 2.0cc - .25 - 1mm
	  	******	  	******	  	******	  	******
						
	 90210
	  	 Tutodent .5cc - 1-2mm
	  	******	  	******	  	******	  	******
	 97210
	  	 CopiOs Cancellous.5cc - 1-2mm
	  	******	  	******	  	******	  	******
						
	 90211
	  	 Tutodent 1.0cc - 1-2mm
	  	******	  	******	  	******	  	******
	 97211
	  	 CopiOs Cancellous 1.0cc - 1-2mm
	  	******	  	******	  	******	  	******
						
	 90212
	  	 Tutodent 2.0cc - 1-2mm
	  	******	  	******	  	******	  	******
	 97212
	  	 CopiOs Cancellous 2.0cc - 1-2mm
	  	******	  	******	  	******	  	******
						
		  	Product Demo Samples (unsterile)	  		  		  		  	
	 97941
	  	 CopiOs Membrane 15 x 20 mm Non Packaged Demo Sample
	  	******	  	******	  	******	  	******
	 97942
	  	 CopiOs Membrane 20 x 30 mm Non Packaged Demo Sample
	  	******	  	******	  	******	  	******
	 97943
	  	 CopiOs Membrane 30x40 mm Non Packaged Demo Sample
	  	******	  	******	  	******	  	******
	 97901
	  	 Bovine Cancellous Microchips .25 -1mmm, 1cc Demo Sample in Vials
	  	******	  	******	  	******	  	******
	 97902
	  	 Bovine Cancellous Microchips 1-2 mm, 1cc Demo Sample in Vials
	  	******	  	******	  	******	  	******
	 97911
	  	 Bovine Cortical Microchips 0.25-1mm, 1cc Demo Sample in vials
	  	******	  	******	  	******	  	******
	 97912
	  	 Bovine Cortical Microchips 1-2mm, 1cc Demo Sample in vials
	  	******	  	******	  	******	  	******
	 97922
	  	 Bovine Cancellous Block 10mmx10mmx10mm Demo Sample
	  	******	  	******	  	******	  	******
	 97002
	  	 CopiOs Membrane 15 x 20 mm Packaged Demo Sample
	  	******	  	******	  	******	  	******
	 97003
	  	 CopiOs Membrane 20 x 30 mm Packaged Demo Sample
	  	******	  	******	  	******	  	******
	 97004
	  	 CopiOs Membrane 30x40 mm Packaged Demo Sample
	  	******	  	******	  	******	  	******
	 97201
	  	 Bovine Cancellous Microchips .25 -1mmm, 1cc Demo Sample packaged
	  	******	  	******	  	******	  	******
	 90211
	  	 Bovine Cancellous Microchips 1-2 mm, 1cc Demo Sample packaged
	  	******	  	******	  	******	  	******

 EXHIBIT A - Continued 
  

  

											
	 EMEA
Part
Numbers
	  	 Brand / Product Description
	  	 Transfer Fee
EMEA
	  	 Lead time
Calendar
Days
	  	 Label
Shelf
Life
	  	 Minimum
Shelf Life

		  	Bovine Pericardium	  		  		  		  	
	 90004
	  	 TUTODENT Membrane 30x40mm
	  	******	  	******	  	******	  	******
	 97004
	  	 CopiOs Pericardium Membrane 30x40mm
	  	******	  	******	  	******	  	******
						
	 90003
	  	 TUTODENT Membrane 20x30mm
	  	******	  	******	  	******	  	******
	 97003
	  	 CopiOs Pericardium Membrane 20x30mm
	  	******	  	******	  	******	  	******
						
	 90002
	  	 TUTODENT Membrane 15x20mm
	  	******	  	******	  	******	  	******
	 97002
	  	 CopiOs Pericardium Membrane 15x20mm
	  	******	  	******	  	******	  	******
						
		  	Human Bone Allograft	  		  		  		  	
	 L10377
	  	 TUTOPLAST Spongiosa Particulate ø 0,25-1mm, 0,5cc
	  	******	  	******	  	******	  	******
	 68710
	  	 TUTOPLAST Spongiosa Particulate ø 0,25-1mm, 0,5cc
	  	******	  	******	  	******	  	******
	 67210
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 0,5cc
	  	******	  	******	  	******	  	******
	 68210
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 0,5cc (US)
	  	******	  	******	  	******	  	******
	 L20308
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 0,5cc
	  	******	  	******	  	******	  	******
						
	 L10378
	  	 TUTOPLASTSpongiosa Particulate ø 0,25-1mm, 1cc
	  	******	  	******	  	******	  	******
	 68711
	  	 TUTOPLASTSpongiosa Particulate ø 0,25-1mm, 1cc
	  	******	  	******	  	******	  	******
	 67211
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 1cc
	  	******	  	******	  	******	  	******
	 68211
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 1cc (US)
	  	******	  	******	  	******	  	******
	 L20309
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 1cc
	  	******	  	******	  	******	  	******
						
	 68712
	  	 TUTOPLAST Spongiosa Particulate ø 0,25-1mm, 2cc
	  	******	  	******	  	******	  	******
	 67209
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 2cc
	  	******	  	******	  	******	  	******
	 68209
	  	 PUROS CANCELLOUS Particulate ø 0,25-1mm, 2cc (US)
	  	******	  	******	  	******	  	******
						
	 L10379
	  	 TUTOPLAST Spongiosa Particulate ø 1-2mm, 0,5cc
	  	******	  	******	  	******	  	******
	 68713
	  	 TUTOPLAST Spongiosa Particulate ø 1-2mm, 0,5cc
	  	******	  	******	  	******	  	******
	 67212
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 0,5cc
	  	******	  	******	  	******	  	******
	 68212
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 0,5cc (US)
	  	******	  	******	  	******	  	******
	 L20410
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 0,5cc
	  	******	  	******	  	******	  	******
						
	 L10380
	  	 TUTOPLAST Spongiosa Particulate ø 1-2mm, 1cc
	  	******	  	******	  	******	  	******
	 68714
	  	 TUTOPLAST Spongiosa Particulate ø 1-2mm, 1cc
	  	******	  	******	  	******	  	******
	 67213
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 1cc
	  	******	  	******	  	******	  	******
	 68213
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 1cc (US)
	  	******	  	******	  	******	  	******
	 L20411
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 1cc
	  	******	  	******	  	******	  	******
						
	 L10381
	  	 TUTOPLAST Spongiosa Particulate ø 1-2mm, 2cc
	  	******	  	******	  	******	  	******
	 68715
	  	 TUTOPLAST Spongiosa Particulate ø 1-2mm, 2cc
	  	******	  	******	  	******	  	******
	 67214
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 2cc
	  	******	  	******	  	******	  	******
	 68214
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 2cc (US)
	  	******	  	******	  	******	  	******

 EXHIBIT A - Continued 
  

											
	 EMEA
Part
Numbers
	  	 Brand / Product Description
	  	 Transfer Fee
EMEA
	  	 Lead time
Calendar
Days
	  	 Label
Shelf
Life
	  	 Minimum
Shelf Life

	 L10319
	  	 TUTOPLAST CANCELLOUS Particulate ø 1-2mm, 3cc
	  	******	  	******	  	******	  	******
	 67215
	  	 PUROS CANCELLOUS Particulate ø 1-2mm, 3cc
	  	******	  	******	  	******	  	******
						
	 L10382
	  	 TUTOPLAST CANCELLOUS Particulate ø 2-4mm, 3cc
	  	******	  	******	  	******	  	******
	 67216
	  	 PUROS CANCELLOUS Particulate ø 2-4mm, 3cc
	  	******	  	******	  	******	  	******
	 68716
	  	 TUTOPLAST CANCELLOUS Particulate ø 2-4mm, 3cc
	  	******	  	******	  	******	  	******
						
	 68735
	  	 TUTOPLAST Cortical Particulate ø 1-2mm, 2cc
	  	******	  	******	  	******	  	******
	 67276
	  	 PUROS Cortical Particulate ø 1-2mm, 2cc
	  	******	  	******	  	******	  	******
	 68276
	  	 PUROS Cortical Particulate ø 1-2mm, 2cc (US)
	  	******	  	******	  	******	  	******
						
	 68734
	  	 TUTOPLAST Cortical Particulate ø 1-2mm, 1cc
	  	******	  	******	  	******	  	******
	 67275
	  	 PUROS Cortical Particulate ø 1-2mm, 1cc
	  	******	  	******	  	******	  	******
	 68275
	  	 PUROS Cortical Particulate ø 1-2mm, 1cc (US)
	  	******	  	******	  	******	  	******
						
	 68733
	  	 TUTOPLAST Cortical Particulate ø 1-2mm, 0,5cc
	  	******	  	******	  	******	  	******
	 67274
	  	 PUROS Cortical Particulate ø 1-2mm, 0,5cc
	  	******	  	******	  	******	  	******
	 68274
	  	 PUROS Cortical Particulate ø 1-2mm, 0,5cc (US)
	  	******	  	******	  	******	  	******
						
	 68732
	  	 TUTOPLAST Cortical Particulate ø 0,25-1mm, 2cc
	  	******	  	******	  	******	  	******
	 67273
	  	 PUROS Cortical Particulate ø 0,25-1mm, 2cc
	  	******	  	******	  	******	  	******
	 68273
	  	 PUROS Cortical Particulate ø 0,25-1mm, 2cc (US)
	  	******	  	******	  	******	  	******
						
	 68731
	  	 TUTOPLAST Cortical Particulate ø 0,25-1mm, 1cc
	  	******	  	******	  	******	  	******
	 67272
	  	 PUROS Cortical Particulate ø 0,25-1mm, 1cc
	  	******	  	******	  	******	  	******
	 68272
	  	 PUROS Cortical Particulate ø 0,25-1mm, 1cc (US)
	  	******	  	******	  	******	  	******
						
	 68730
	  	 TUTOPLAST Cortical Particulate ø 0,25-1mm, 0,5cc
	  	******	  	******	  	******	  	******
	 67271
	  	 PUROS Cortical Particulate ø 0,25-1mm, 0,5cc
	  	******	  	******	  	******	  	******
	 68271
	  	 PUROS Cortical Particulate ø 0,25-1mm, 0,5cc (US)
	  	******	  	******	  	******	  	******
						
	 L10386
	  	 TUTOPLAST Spongiosa Block-P 15x10x9mm
	  	******	  	******	  	******	  	******
	 68737
	  	 TUTOPLAST Spongiosa Block-P15x10x9mm
	  	******	  	******	  	******	  	******
	 67220
	  	 PUROS Corticospongiosa Block 15x10x9mm
	  	******	  	******	  	******	  	******
	 68220
	  	 Puros Block US Design
	  	******	  	******	  	******	  	******
						
	 L10385
	  	 TUTOPLAST Spongiosa Block-P 15x15x9mm
	  	******	  	******	  	******	  	******
	 68736
	  	 TUTOPLAST Spongiosa Block-P 15x15x9mm
	  	******	  	******	  	******	  	******
	 67221
	  	 PUROS Corticospongiosa Block 15x15x9mm
	  	******	  	******	  	******	  	******
	 68221
	  	 Puros Block US Design
	  	******	  	******	  	******	  	******
						
	 L10384
	  	 Tutoplast Spongiasa Dowel ø 7mm, L14-18mm
	  	******	  	******	  	******	  	******
	 67225
	  	 Puros Cancellous Dowel ø 7mm, L14-18mm
	  	******	  	******	  	******	  	******

 EXHIBIT A - Continued 
  

											
	 EMEA
Part
Numbers
	  	 Brand / Product Description
	  	 Transfer Fee
EMEA
	  	 Lead time
Calendar
Days
	  	 Label
Shelf
Life
	  	 Minimum
Shelf Life

	 L10383
	  	 Tutoplast Spongiasa Block, 8x8x8mm
	  	******	  	******	  	******	  	******
	 67222
	  	 Puros Cancellous Block, 8x8x8mm
	  	******	  	******	  	******	  	******
	 L10367
	  	 Tutoplast Spongiasa Dowel ø 10mm, L16-20mm
	  	******	  	******	  	******	  	******
	 67226
	  	 Puros Cancellous Dowel ø 10mm, L 16-20mm
	  	******	  	******	  	******	  	******
						
	 L10365
	  	 Tutoplast Spongiosa block 10x10x20mm
	  	******	  	******	  	******	  	******
	 67223
	  	 PUROS cancellous block 10x10x20mm
	  	******	  	******	  	******	  	******
						
	 L10302
	  	 Tutoplast Spongiasa Block 10x20x20mm
	  	******	  	******	  	******	  	******
	 67224
	  	 Puros Cancellous Block 10x20x20mm
	  	******	  	******	  	******	  	******
					
	Allograft Membranes	  		  		  		  	
	 68700
	  	 Tutodent Dermis 1,5 x 2 cm
	  	******	  	******	  	******	  	******
	 68701
	  	 Tutodent Dermis 2 x 3 cm
	  	******	  	******	  	******	  	******
	 68702
	  	 Tutodent Dermis 3 x 4 cm
	  	******	  	******	  	******	  	******
						
	 67790
	  	 Puros Dermis Dental Membrane 10 x 20 mm
	  	******	  	******	  	******	  	******
	 67791
	  	 Puros Dermis Dental Membrane 10 x 40 mm
	  	******	  	******	  	******	  	******
	 67792
	  	 Puros Dermis Dental Membrane 20 x 40 mm
	  	******	  	******	  	******	  	******
	 67793
	  	 Puros Dermis Dental Membrane 10 x 10 mm
	  	******	  	******	  	******	  	******
	 67794
	  	 Puros Dermis Allograft 0.3-0.8 mm 10 x 10 mm
	  	******	  	******	  	******	  	******
	 67795
	  	 Puros Dermis Allograft 0.3-0.8 mm 10 x 20 mm
	  	******	  	******	  	******	  	******
	 67796
	  	 Puros Dermis Allograft 0.3-0.8 mm 10 x 40 mm
	  	******	  	******	  	******	  	******
	 67797
	  	 Puros Dermis Allograft 0.3-0.8 mm 20 x 40 mm
	  	******	  	******	  	******	  	******
						
	 68770
	  	 15 X 20 mm Puros Pericardium
	  	******	  	******	  	******	  	******
	 68771
	  	 20 X 30 mm Puros Pericardium
	  	******	  	******	  	******	  	******
	 68772
	  	 30 X 40 mm Puros Pericardium
	  	******	  	******	  	******	  	******
						
		  	Bovine Bone	  		  		  		  	
	 90101
	  	 Tutodent Block 10x10x20
	  	******	  	******	  	******	  	******
	 90280
	  	 Tutodent CS - Block 15mm x 10mm x 5,5mm
	  	******	  	******	  	******	  	******
	 90282
	  	 Tutodent CS - Block 15mm x 15mm x 5,5mm
	  	******	  	******	  	******	  	******
						
	 90200
	  	 Tutodent .5cc - .25-1mm (CopiOs Cancellous Particulate)
	  	******	  	******	  	******	  	******
	 90201
	  	 Tutodent 1.0cc - .25-1mm (CopiOs CancellouS Particulate)
	  	******	  	******	  	******	  	******
	 90202
	  	 Tutodent 2.0cc - .25 - 1mm (CopiOs Cancellous Particulate)
	  	******	  	******	  	******	  	******
	 90210
	  	 Tutodent .5cc - 1-2mm (CopiOs Cancellous Particulate)
	  	******	  	******	  	******	  	******
	 90211
	  	 Tutodent 1.0cc - 1-2mm (CopiOs Cancellous Particulate)
	  	******	  	******	  	******	  	******
	 90212
	  	 Tutodent 2.0cc - 1-2mm (CopiOS Cancellous Particulate)
	  	******	  	******	  	******	  	******

 EXHIBIT A - Continued 
  

											
	 EMEA
Part
Numbers
	  	 Brand / Product Description
	  	 Transfer Fee
EMEA
	  	 Lead time
Calendar
Days
	  	 Label
Shelf
Life
	  	 Minimum
Shelf Life

						
		  	Product Demo Samples (unsterile)	  		  		  		  	
	 97941
	  	CopiOs Membrane 15 x 20 mm Non Packaged Demo Sample	  	******	  	******	  	******	  	******
	 97942
	  	CopiOs Membrane 20 x 30 mm Non Packaged Demo Sample	  	******	  	******	  	******	  	******
	 97943
	  	CopiOs Membrane 30x40 mm Non Packaged Demo Sample	  	******	  	******	  	******	  	******
	 97901
	  	Bovine Cancellous Microchips ø .25 -1mmm, 1cc Demo Sample in Vials	  	******	  	******	  	******	  	******
	 97902
	  	Bovine Cancellous Microchips ø 1-2 mm, 1cc Demo Sample in Vials	  	******	  	******	  	******	  	******
	 97911
	  	Bovine Cortical Microchips ø 0.25-1mm, 1cc Demo Sample in vials	  	******	  	******	  	******	  	******
	 97912
	  	Bovine Cortical Microchips ø 1-2mm, 1cc Demo Sample in vials	  	******	  	******	  	******	  	******
	 97922
	  	Bovine Cancellous Block 10mmx10mmx10mm Demo Sample	  	******	  	******	  	******	  	******
		  	CopiOs Membrane 15 x 20 mm Packaged Demo Sample	  	******	  	******	  	******	  	******
		  	CopiOs Membrane 20 x 30 mm Packaged Demo Sample	  	******	  	******	  	******	  	******
		  	CopiOs Membrane 30 x 40 mm Packaged Demo Sample	  	******	  	******	  	******	  	******
		  	Bovine Cancellous Microchips ø .25 -1mmm, 1cc Demo Sample packaged	  	******	  	******	  	******	  	******
		  	Bovine Cancellous Microchips ø 1-2 mm, 1cc Demo Sample packaged	  	******	  	******	  	******	  	******
		  	Bovine Cortical Microchips ø 0.25-1mm, 1cc Demo Sample Packaged	  	******	  	******	  	******	  	******
		  	Bovine Cortical Microchips ø 1-2mm, 1cc Demo Sample Packaged	  	******	  	******	  	******	  	******

 RTI agrees to consolidate part numbers upon
Zimmer’s request to simplify part numbers into two sets: 
  

	 	1.	EMEA (current EMEA Part Numbers) 

  

	 	2.	All Other Areas (current US Part Numbers) 

 RTI
and Zimmer will in good faith endeavor to develop a plan to consolidate Part Numbers within ninety (90) days of the expiration or earlier termination of the Transition Services Agreement, Exhibit D. RTI will be allowed to run out existing
labeled inventory during the transition. 

  
 EXHIBIT B

 Territory 
 Ukraine 
 ** The Parties acknowledge and agree that within five (5) Business Days after
execution of this Agreement, RTI shall deliver notice of termination for any and all agreements with third party distributors (******) in ****** in order to terminate such agreements as soon as possible in accordance with the terms of the notice
provisions of the respective agreements. 

  
 EXHIBIT C

 Existing Agreement Implants 

 

							
	Class	  	Subclass	 	Description	  	Preservation
				
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
	 ******
	  	******	 	******	  	******
		  	******	 	******	  	******

  
 EXHIBIT D

 TRANSITION SERVICES AGREEMENT 
 This Transition Services Agreement (this “Agreement”) is made and entered into as of September 30, 2010 (the “Effective Date”), by and between Zimmer Dental, Inc., a
Delaware corporation (“Zimmer”), and RTI Biologics, Inc., a Delaware corporation (“RTI”). 

Recitals 
 A. Contemporaneously with the execution of this Agreement, Zimmer and RTI are entering into an Exclusive Distribution Agreement (the “Distribution Agreement”) for the distribution by
Zimmer of certain allograft and xenograft biologic implants prepared and processed by RTI (as specifically defined in the Distribution Agreement, the “Implants”). The Distribution Agreement supersedes and replaces certain prior
agreements between the parties and/or their Affiliates for the distribution of the Implants, including the U.S. Agreement, as further described in the Distribution Agreement. 

B. In connection with the implementation of the Distribution Agreement, Zimmer desires to engage RTI to provide certain transition
services, and RTI is willing to provide such services pursuant to this Agreement. 
 C. Unless otherwise defined herein,
capitalized terms used in this Agreement shall have the meanings given to them in the Distribution Agreement. 
 Agreement

 In consideration of the mutual covenants contained in this Agreement, Zimmer and RTI agree as follows: 

1. Consignment of Implants. Pursuant to Section 3.5 of the Distribution Agreement, Zimmer will submit to RTI a binding
initial stocking order for Implants upon execution of the Distribution Agreement. The initial stocking order will be fulfilled by RTI in partial shipments in accordance with the terms of the order and the Distribution Agreement. In addition, during
the Transition Period (as defined below) and prior to October 15, 2010, Zimmer will use commercially reasonable efforts to submit Forecasted Firm Orders and/or Additional Orders to RTI in an amount reasonably estimated by Zimmer (based on
trailing six (6) months of Implant sales) to be sufficient to result in Zimmer holding an inventory of Implants with aggregate Fees in an amount no less than ****** USD on or prior to December 31, 2010. Except for Implants shipped at
Zimmer’s request to its facility in Memphis, Tennessee for purposes of building inventory in preparation for assuming the full scope of its responsibilities under the Distribution Agreement, each partial shipment of the Implants subject to the
initial stocking order and each Forecasted Firm Order and Additional Orders, if any, placed by Zimmer during the Transition Period will be consigned to RTI and held during the Transition Period at RTI’s facility in Alachua, Florida, pursuant to
the terms and conditions of this Agreement. Within ten (10) Business Days following the expiration or earlier termination of the Transition Period, Zimmer will accept shipment of all consigned Implants held by RTI. 

  
 2. Transition
Services. During the Transition Period, RTI shall provide the following transition services (“Services”) to Zimmer: 
 (a) RTI shall receive and fulfill customer orders for Implants placed by Zimmer’s U.S. customers, in a manner consistent with the services provided by RTI’s Affiliate under the U.S.
Agreement as in effect immediately prior to the Effective Date. 
 (b) RTI shall ship the Implants to Zimmer’s
customers from the consigned inventory of Implants held by RTI, pursuant to the applicable customer orders and in a manner consistent with the services provided by RTI’s Affiliate under the U.S. Agreement as in effect immediately prior to the
Effective Date. 
 (c) RTI shall invoice Zimmer’s customers and collect fees for the transfer of the Implants to
Zimmer’s customers (“Customer Fees”) in a manner consistent with the services provided by RTI’s Affiliate under the U.S. Agreement as in effect immediately prior to the Effective Date. RTI shall remit such Customer Fees to
Zimmer, less any shipping costs and credit card service fees. RTI shall remit such payments on the first and fifteenth day of each calendar month during the Transition Period (or the next Business Day following such date(s) if such date(s) are not
Business Days). Upon the expiration or earlier termination of the Transition Period, Zimmer will assume responsibility for collecting all outstanding receivables incurred after the Effective Date for Implants ordered by Zimmer’s customers.

 (d) RTI shall provide written reports to Zimmer on the first and fifteenth day of each calendar month during the
Transition Period (or the next Business Day following such date(s) if such date(s) are not Business Days). The specific schedule and deadlines for such reports are summarized on Exhibit A attached to this Agreement. RTI shall keep accurate
records in sufficient detail to enable the Customer Fees due to Zimmer to be determined. During the Transition Period and for a period of one (1) calendar year after the termination of the Transition Period, Zimmer shall have the right to
inspect RTI’s records from the Transition Period for the purpose of determining the accuracy of Customer Fees paid to Zimmer. 
 (e) RTI shall provide Zimmer access to the Alachua, Florida facility, at mutually agreeable times and with reasonable prior notice, for the purpose of inspecting the Implants held in consignment
for reconciliation to the initial stocking order and applicable Forecasted Firm Orders within a reasonable period of time after each shipment of Implants is consigned to RTI during the Transition Period. Zimmer’s obligations to inspect
shipments for shortage and nonconformance with the applicable order under the Distribution Agreement will be modified during the Transition Period to allow Zimmer a reasonable period of time to complete such inspection at the Alachua, Florida
facility. 
 To the extent that the terms of Section 1 of this Agreement are inconsistent with the terms of Sections 3.3, 3.4, 3.5, 3.6,
3.7, and 3.8 of the Distribution Agreement, the terms of Section 1 of this Agreement shall govern and control during the Transition Period. 

  
 3.
Compensation. As consideration for its performance of the Services: (i) from the Effective Date through January 1, 2011, RTI shall be entitled to a fixed monthly fee equal to ****** (USD) per month (prorated for any partial month); and
(ii) after January 1, 2011 and through the remainder of the Transition Period, RTI shall be entitled to a fixed monthly fee equal ****** (USD) per month (prorated for any partial month) (the “Service Fee”) Zimmer shall pay the
Service Fee to RTI within ten (10) Business Days following the end of the month in which such Services were provided. In the event that RTI is unable to ship ****** so that Zimmer may assume its full scope of responsibilities under the
Distribution Agreement, RTI shall not be entitled the then applicable Service Fee (prorated for any partial month). 
 4.
Transition Period. The initial term of this Agreement shall commence on the Effective Date and shall expire on June 30, 2011 (the “Initial Transition Period”). Upon mutual written agreement, the parties may extend the term of this
Agreement beyond the Initial Transition Period (the “Extended Transition Period”). The Initial Transition Period and the Extended Transition Period are collectively referred to herein as the “Transition Period.” Zimmer may
terminate this Transition Services Agreement prior to the expiration of the Transition Period, provided that Zimmer shall deliver to RTI a written termination notice no less than ten (10) Business Days prior to the desired effective date of
such termination. Zimmer will use commercially reasonable efforts to assume its full scope of responsibilities under the Distribution Agreement by January 1, 2011, or as soon as reasonably practicable thereafter. RTI will use commercially
reasonable efforts to assist Zimmer to assume its full scope of responsibilities under the Distribution Agreement by January 1, 2011. 
 5. Title and Risk of Loss. All Implants consigned to RTI pursuant to this Agreement will be owned by Zimmer and, Zimmer will have title to all such Implants until transfer to Zimmer’s
customers. (As used in this Agreement with respect to allograft based Implants, the terms “owned” and “title,” including word variations thereof, shall refer to such legal or equitable rights of possession or control as allowed
by law). RTI will be responsible for storing the Implants consigned to RTI in a manner consistent with Specifications, Applicable Industry Standards and Applicable Laws and shall take commercially reasonable efforts to protect such Implants from all
losses resulting from theft, damage to or destruction of the Implants from the time of consignment until transfer to Zimmer’s customers. RTI will be responsible for all losses resulting from theft, damage to or destruction of the consigned
Implants caused by the intentional misconduct or negligence of RTI or any of its employees. RTI may not transfer ownership of the consigned Implants as collateral or security, nor as a mortgage nor encumber the consigned Implants in any other way in
favor of Third Parties. RTI shall take such action and execute and deliver such documents as Zimmer may reasonably request to protect, and maintain the protection of, Zimmer’s rights in the consigned Implants, including filing financing and
other similar statements as may be required to protect Zimmer’s ownership in any applicable jurisdiction. 
 6.
Confidentiality. The provisions in Article 7 of the Distribution Agreement shall apply to any information disclosed in connection with this Agreement. 
 7. Agency. The Parties are independent contractors. Neither Party is, nor shall be deemed to be, an employee, agent, partner or legal representative of the other Party for any

 
purpose. Neither Party, nor its affiliates, employees, officers or agents, shall have the right, power or authority to enter into any contracts in the name of, or on behalf of, the other Party,
nor shall either Party, nor its affiliates, employees, officers or agents, have the right, power or authority to pledge the credit of the other Party in any way or hold itself out as having the authority to do so. 

8. Entire Agreement; Amendments. This Agreement constitutes the entire agreement between the Parties hereto concerning its subject
matter and supersedes all previous negotiations, agreements and commitments with respect thereto. This Agreement shall not be released, discharged, amended or modified in any manner except by a written instrument signed by duly authorized officers
or representatives of each of the Parties hereto. 
 9. Governing Law. This Agreement shall be governed by and
interpreted in accordance with the substantive laws of the State of Illinois, without regard to its choice of law rules. 

10. Waiver of Compliance. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its
agents or employees, except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party, which waiver shall be effective only with respect to the specific obligation and instance
described therein. 
 11. Notices. All notices and other communications in connection with this Agreement shall be in
writing and shall be sent to the respective Parties at their addresses set forth in the Distribution Agreement. All notices shall be deemed given and received (i) if delivered by hand, immediately, (ii) if sent by mail, three (3)
Business Days after posting, (iii) if delivered by express courier service, the next Business Day in the jurisdiction of the recipient or (iv) if sent by fax, at the time shown in the confirmed electronic receipt, or on the first Business
day thereafter if the notice is not sent on a Business Day. 
 12. Counterparts and Facsimile/Electronic Delivery. This
Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument. A manual signature on this Agreement or any document executed in connection with
this Agreement, the image of which is transmitted electronically (including facsimile or e-mail), shall constitute an original signature for purposes of this Agreement. 
 13. Assignment. Neither Party shall have the right to assign any of its rights or obligations under this Agreement without the prior written consent of the other Party. Any assignment not in
accordance with this Section 13 shall be void. 
 [SIGNATURES ON FOLLOWING PAGE; 

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 IN WITNESS WHEREOF,
each Party has caused this Agreement to be executed by its respective duly authorized representative as of the Effective Date. 
  

			
	RTI BIOLOGICS, INC.

			
		
	By:	 	  

			
		
	Name:	 	  

			
		
	Title:	 	  

			
	
	ZIMMER DENTAL, INC.

			
		
	By:	 	  

			
		
	Name:	 	  

			
		
	Title:	 	  

  
 EXHIBIT A to
Transition Services Agreement 
 Data and Reports to Be Provided to Zimmer 

(All days are in Business Days) 
  

					
	Description	  	Timing	 	Due Date
			
	 Detailed Sales Report
 (in the
format provided by Zimmer)
	  	Monthly	 	 1st day of the month
 by
10:00 a.m. (E.S.T.)

			
	 Accounts Receivable Aging Report by
     Customer by Invoice
	  	Monthly	 	 1st day of the month
 by
10:00 a.m. (E.S.T.)

			
	Cash Receipts Report by Customer, by Invoice	  	Monthly	 	 1st day of the month
 by
10:00 a.m. (E.S.T.)

			
	Inventory Report by SKU	  	Monthly	 	 1st day of the month
 by
5:00 p.m. (E.S.T.)

			
	Inventory Report by SKU	  	Initial Purchase	 	 Upon “Delivery” to

consigned RTI

location

  
 EXHIBIT E-1

 Marketing Approvals 
 ******** 

  
 EXHIBIT E-2

 Puros brand Implants: 

Country 
 ******** 

 EXHIBIT E-2 Continued 
  

  
 CopiOs brand Implants:

 ******** 

  
 EXHIBIT F

 QUALITY AGREEMENT 
  

	1.0	PURPOSE 

 This Quality
Agreement is an Exhibit to the Exclusive Distribution Agreement, dated September 30, 2010, by and between Zimmer Dental, Inc. and RTI Biologics, Inc. (“Exclusive Distribution Agreement”). This Quality Agreement defines and
documents the responsibilities of Zimmer Dental, Inc. (referred to herein as “Zimmer”) and RTI Biologics, Inc. (referred to herein as “RTI”) wherein Zimmer is the Distributor and RTI is the Manufacturer (or Original
Equipment Manufacturer (“OEM”)), as defined below, of the Complete and Finished Medical Implants. Zimmer and RTI shall hereinafter be referred to collectively as the “Parties” and individually as the
“Party”. 
  

	2.0	DEFINITIONS  

 Defined
terms not defined herein shall have the meaning set forth in the Exclusive Distribution Agreement. 
  

	 	2.1	Complete and Finished Medical Implant – Any medical implant, biologic, tissue implant, or combination implant that is suitable for use, capable of
functioning and is in its final distributable form (i.e. cleaned, labeled, sterilized, etc.), as received by Zimmer. In the context of this Quality Agreement, “Implant” shall refer to those components as set forth in Exhibit A of
the Exclusive Distribution Agreement. 

  

	 	2.2	Interface Document – A document that captures the key attributes of an implant, for the purpose of providing Zimmer personnel with critical information
about the implant without the need to create and maintain comprehensive drawings or specifications. The interface document may be in the form of a drawing, implant specification, and/or other format. 

 

	 	2.3	Manufacturer – The entity who designs, manufactures, fabricates, assembles, or processes a complete and finished medical Implant, including but not limited
to those who perform the functions of contract sterilization, installation, relabeling, remanufacturing, repacking, or specifications development, and initial distributors of foreign entities performing these functions, and who is responsible for it
on the market, as displayed on the labeling. For the Implants, RTI is the legal Manufacturer, and will be identified as such on the labeling. 

  

	 	2.4	 Major Change – A major change is any change that may affect the safety or intended use of the finished implant, including but not limited
to 

	 	 
changes in design, materials, Product Code Number, cleaning, sterilization, and the manufacturing process. A major change will usually affect the Interface Document. 

 

	 	2.5	Quality Agreement – A document (referred to herein as the “QA Agreement”) defining the activities that need to be accomplished, who is
responsible for completing the activities, and in some circumstances the method of accomplishing those activities, in order for Zimmer and the RTI to achieve the shared goals of the two businesses. 

 

	3.0	QUALITY AGREEMENT PERIOD 

  

	 	3.1	This QA Agreement is valid for so long as the Exclusive Distribution Agreement is in effect. This Agreement may be revised by the written consent of the Parties at
anytime during the validity period. 

  

	4.0	DESIGN OF IMPLANT 

  

	 	4.1	RTI is the legal Manufacturer of the Implants, and is responsible for all aspects of design control. 

 

	 	4.2	RTI shall maintain appropriate and required documentation to support design control and document change control activities. 

 

	 	4.3	RTI shall be responsible for all design control and process control activities relative to the Implants, including but not limited to, design assurance and product and
process validations, as required by the cGTP, Quality System Regulations (“QSR”), International Standards Organization (“ISO Standards”), and Applicable Laws. 

 

	5.0	DOCUMENT CHANGE CONTROL 

  

	 	5.1	RTI shall be responsible for managing an effective document change control system relative to the design, manufacture, and labeling of the Implants.

  

	6.0	VALIDATION  

  

	 	6.1	RTI shall be responsible for managing an effective product and process validation system relative to the design and manufacture of the Implants.

  

	 	6.2	RTI shall develop and implement validations or qualification protocols for significant processes, equipment, and computer systems. 

  

	7.0	PROCESS CONTROLS 

  

	 	7.1	RTI shall maintain appropriate documented procedures. 

  

	8.0	HANDLING, STORAGE AND DISTRIBUTION 

  

	 	8.1	Manufacturer shall deliver Implants to the Point of Destination designated by Zimmer using documented procedures for the handling, storage, packaging, preservation, and
delivery of the Implants. The shipping container shall be qualified to ensure that the safety and integrity of the Implant is maintained during transit. 

  

	 	8.2	Zimmer shall deliver Implants to its customers using documented procedures for handling, storage, packing, preservation, and delivery of the Implants.

  

	 	8.3	Zimmer shall store and distribute Implants to its customers using documented procedures for handling, storage and distribution that are appropriate to the environmental
limitation of the Implant. Zimmer’s tissue bank facility will be qualified to ensure proper storage conditions are maintained. 

  

	9.0	LOT CONTROL AND TRACEABILITY  

  

	 	9.1	RTI shall establish and maintain procedures for identifying and tracking each Implant by suitable means from donor through all stages of production and to final
consignee or final disposition. 

  

	 	9.2	Zimmer shall establish and maintain procedures for identifying and tracking the Implant from receipt from RTI through distribution to the final consignee.

  

	 	9.3	RTI will provide a Tissue Utilization Record (TUR) with each human tissue implant. The attending surgeon shall be instructed to complete and return the TUR to RTI.

  

	 	9.4	The Parties shall use reasonable efforts to assist the other in maintaining respective donor lot traceability. 

 

	 	9.5	Zimmer shall provide to RTI information regarding disposition of Implant destroyed by Zimmer, upon request, and will submit destruction records to RTI.

  

	10.0	PACKAGING AND LABELING 

  

	 	10.1	RTI shall be responsible for validating that the packaging system maintains the integrity of the Implant for its labeled shelf life, when stored under labeled
conditions. 

  

	 	10.2	RTI shall ensure that the packaging and labeling of the finished medical implant conforms to Specifications and to Applicable Laws. 

 

	 	10.3	Implant labeling, including instructions for use and other accompanying documents, will be reviewed and approved by required Zimmer functional areas (per applicable
SOP) prior to release of final Implant labeling. 

  

	 	10.4	RTI shall be responsible for obtaining all local language labeling (translations) required for distribution in the Territory as requested by Zimmer. Zimmer shall bear
the cost of all necessary translation services associated with the translations. Prior to incurring any such cost, RTI will submit to Zimmer a written budget showing in reasonable detail the anticipated costs to be incurred for translation services
and will obtain Zimmer’s written approval of such budget before incurring such costs. Zimmer will not be required to reimburse RTI for any translation services costs in excess of the budget unless RTI obtains Zimmer’s prior approval for
the excess costs. 

  

	 	10.5	Zimmer shall not modify the labels, inserts or accompanying documentation without written approval of RTI Regulatory Affairs. 

 

	 	10.6	Promotional materials created by Zimmer shall be approved by RTI Regulatory Affairs for compliance with Applicable Laws. RTI Regulatory Affairs shall provide comments
or approval to Zimmer within ten (10) Business Days of receipt of the promotional material. 

  

	11.0	STERILITY ASSURANCE 

  

	 	11.1	For all sterile Implants, RTI will maintain documentation that sterilization of the Implant conforms to the Applicable Laws and ISO Standards. As applicable, RTI will
provide certification of irradiation for each shipment received at Zimmer. 

  

	 	11.2	RTI will assure that all sterilization process validations and subsequent quarterly dose audits follow AAMI/ISO guidelines. 

 

	 	11.3	RTI will notify Zimmer in writing of any dose audit failure and/or deviations from validated sterilization processes relevant to the Implants. 

  

	12.0	MANUFACTURING AND QUALITY CONTROL 

  

	 	12.1	RTI shall establish and maintain a quality system for all stages of manufacture of the Implants, including donor eligibility and procurement of tissue, in compliance
with Applicable Laws and Applicable Industry Standards, such as 21 CFR 1271, parts 820 and ISO 13485. 

  

	 	12.2	RTI shall establish and maintain an effective product and process validation system relative to all aspects of quality, e.g., design, sterilization and packaging.

  

	 	12.3	RTI shall manage an effective document change control system relative to all aspects of the design, manufacture, storage, and distribution of the Implants.

  

	 	12.3.1	Prior to making a Major Change to an Implant, RTI will submit written notice of the Major Change to Zimmer’s Director of RA/QA, via fax or email. This notice shall
include a full description of the Major Change with adequate information to determine its impact on the finished Implant Specifications and regulatory status. 

 

	 	12.3.2	Zimmer will review and respond to RTI within fifteen (15) Business Days of receipt of Major Change notice. If the Major Change is being implemented to improve the
safety of the Implant, RTI will implement the change as soon as reasonably possible without prior approval by Zimmer. 

  

	 	12.4	RTI shall ensure that its tissue procurement organization and contract suppliers maintain a quality program/system, in compliance with Applicable Laws and Applicable
Industry Standards e.g., 21 CFR 1271, United States Department of Agriculture (“USDA”) , EN 12442, as appropriate for the materials and components e.g., bovine bone, bovine tissue, human bone, human tissue. 

 

	 	12.5	Zimmer shall establish and maintain a quality system in compliance with applicable sections of Applicable Laws, e.g., 21 CFR 1271, 820 and ISO 13485.

  

	13.0	COMMUNICATION AND NOTIFICATION OF QUALITY AND REGULATORY MATTERS 

  

	 	13.1	Zimmer Regulatory Affairs and RTI Regulatory Affairs will notify the other in writing, of quality and regulatory issues applicable to Implants acquired by Zimmer
customers, including but not limited to: 

  

	 	13.1.1	Regulatory actions by Governmental Authorities e.g., issuance of Form 483, retention/destruction/recall of implant, against Zimmer, RTI or its tissue procurement
organization which are relevant to the Implants. 

  

	 	13.1.2	Implant/component non-conformances or manufacturing deviations. 

  

	 	13.2	The Parties shall cooperate in response to any issue, including providing information and documentation as requested by the Regulatory Authority (with copies of any
such information and documentation to be provided to the other Party). If the issue primarily concerns Zimmer’s activities, then Zimmer shall have primary responsibility to respond to the Regulatory Authority; otherwise, RTI shall have primary
responsibility to respond. In either case, upon request of the responding Party, the other Party shall provide consulting advice and assistance with the response. 

 

	14.0	POSTMARKET SURVEILLANCE 

  

	 	14.1	Any Zimmer representative or employee who first receives knowledge of a Third Party Complaint or Adverse Event shall notify the Compliance / Postmarket Surveillance
function of Zimmer in accordance with established procedures. 

  

	 	14.2	The Compliance / Postmarket Surveillance department or appropriate functional area of Zimmer will initiate a report form for each complaint received, according to
established procedures. 

  

	 	14.3	The Zimmer Carlsbad Compliance / Postmarket Surveillance department will file the information received and will notify RTI’s Quality Systems group within
RTI’s Quality Assurance department of the Third Party Complaint or Adverse Event within seventy-two (72) hours of receipt of such information by Zimmer Carlsbad Compliance/ Postmarket Surveillance department, except for an Adverse Event
that is fatal, results in serious injury, or necessitates medical intervention in order to prevent permanent injury or impairment, for which a report will be sent to RTI within twenty-four (24) hours of receipt of such information.

  

	 	14.4	RTI’s Quality Systems group will investigate the complaint / event and report it to the FDA and/or other Regulatory Authority if required. RTI will send a copy of
the completed investigation to Zimmer Compliance / Postmarket Surveillance for Zimmer’s files. 

  

	 	14.5	RTI shall notify Zimmer Regulatory Compliance in writing of any legal and regulatory matter relating to the Implants, including: 

 

	 	14.5.1	Any regulatory actions by Governmental Authorities (e.g., inspection citations, warning letters, or other non-conformance notices). 

 

	 	14.5.2	Regulatory enforcement action such as injunctions or seizures. 

  

	 	14.5.3	FDA registration activity (e.g., non-conformance notices, hold points). 

  

	 	14.5.4	Complaints received from Zimmer’s customers that have not been processed through Zimmer’s complaint handling system. 

 

	 	14.5.5	Adverse incidents relating to Zimmer’s customers (e.g., MedWatch reports). 

 

	 	14.6	Zimmer and RTI will inform each other as soon as reasonably possible about all clinical findings regarding safe and effective use of the Implants.

  

	 	14.7	Returns of Implants will be processed in accordance with the procedures set forth on Schedule B. Complaints will be registered with Zimmer and Zimmer’s customer
will return the Implants to Zimmer. Prior to returning any Implant to RTI, Zimmer will acquire the return authorization number from RTI. 

  

	15.0	FIELD ACTIONS  

  

	 	15.1	RTI will be responsible for the initiation of any Field Actions related to the Implants. 

 

	 	15.2	 RTI will notify Zimmer Regulatory Compliance to request cooperation with any Field Action that affect an Implant Distributed by Zimmer. RTI will ensure
that any Field Actions comply with the requirements of the FDA and/or applicable international Regulatory Authorities. If it was caused primarily by the negligent (or more culpable) action (including misstatements) or omission by Zimmer or one of
its Affiliates or Marketing Partners, then Zimmer shall bear the related expense; otherwise, RTI shall reimburse Zimmer for Zimmer’s reasonable expenses 

	 	 
and either replace the affected Implants free of charge or, at Zimmer’s election, refund to Zimmer the entire Fee paid for the affected Implants. RTI shall be responsible for any required
reporting to Regulatory Authorities. 

  

	 	15.3	Zimmer will comply with any recall or general corrective actions initiated by RTI involving the Implants, provided such recalls or general corrective actions do not, in
the opinion of Zimmer, violate or cause Zimmer to violate the laws of any jurisdiction affected by the recalls or corrective actions. 

  

	16.0	AUDITS 

  

	 	16.1	Zimmer shall have the right, upon reasonable prior notice to RTI, to inspect and audit RTI’s facilities and operations for the purpose of verifying RTI’s
compliance with its obligations under this Agreement and satisfying all Zimmer quality system requirements, including the right to (a) inspect and take samples of the Implants, (b) observe Manufacturing and related operations, procedures
and methods, (c) review documentation and (d) conduct quality assurance, quality system and regulatory compliance audits. Audits will be scheduled at mutually convenient times, such schedule not being subject to unreasonable delay or
hindrance. During audits of RTI, Zimmer will only have access to the physical areas and procedures pertinent to the Implants. Zimmer will copy RTI on any written audit report within thirty (30) days of report completion. RTI will develop and
provide a written corrective/preventive action plan for any non-conformances cited within sixty (60) days of written notification by Zimmer. 

  

	 	16.2	RTI shall have the right, upon reasonable prior notice to Zimmer, to inspect and audit Zimmer’s tissue bank facilities and operations for the purpose of verifying
Zimmer’s compliance with its obligations under this Agreement and satisfying all RTI quality system requirements, including the right to (a) review documentation and (b) conduct quality assurance, quality system and regulatory
compliance audits. Audits will be scheduled at mutually convenient times, such schedule not being subject to unreasonable delay or hindrance. During audits of Zimmer, RTI will only have access to the physical areas and procedures pertinent to the
Implants. RTI will copy Zimmer on any written audit report within thirty (30) days of report completion. Zimmer will develop and provide a written corrective/preventive action plan for any non-conformances cited with sixty (60) days of
written notification by RTI. 

  

	 	16.3	Zimmer and RTI will inform the other as soon as practicable of any negative outcomes resulting from an audit by a Regulatory Authority or accreditation authority
relating to Implants under this QA Agreement. 

  

	17.0	LOT TEST, LOT RELEASE AND ACCEPTANCE REQUIREMENTS 

  

	 	17.1	RTI shall establish and maintain documented procedures for acceptance criteria and release testing for incoming material and finished Implants to ensure that each lot
of Implants delivered to Zimmer conforms to the Specifications and regulatory approvals. 

  

	 	17.2	Zimmer, upon receipt, shall inspect or otherwise verify that finished Implants conform to Specifications. If any Implant is deemed not to meet Specifications, Zimmer
shall return the Implant to RTI. 

  

	 	17.3	RTI will provide a Certificate of Conformance and any needed shipping documents for each product lot, in a format agreed upon by both Parties, to the Zimmer tissue
facility stating that the Implants shipped conform to the Specifications. 

  

	18.0	RECORD RETENTION REQUIREMENTS 

  

	 	18.1	The Parties shall retain all applicable records e.g., implant master record, complaint files, for at least the minimum of time required by Applicable Laws.

  

	19.0	REGULATORY ACTIVITIES  

  

	 	19.1	RTI Regulatory Affairs shall notify Zimmer Regulatory Affairs of information regarding changes to the regulatory status of any Implant. 

 

	 	19.2	RTI Regulatory Affairs shall submit and maintain the required establishment registration and implant listing information as required under the Exclusive Distribution
Agreement. 

  

	20.	COMPLIANCE WITH LAWS 

  

	 	20.1	RTI and Zimmer shall each comply in all material respects with all Applicable Laws and Applicable Industry Standards that pertain to its activities under the Exclusive
Distribution Agreement and, except as otherwise provided for herein, shall bear the entire cost and expense of such compliance. For avoidance of doubt, and without limiting the generality of the foregoing, each Party shall be responsible for costs
and expenses incurred by such Party in order to maintain quality systems and applicable certifications in compliance with United States quality systems regulations, Medical Device Directives (“MDD”), AATB and ISO 13485.

  
 In witness whereof,
the Parties have each caused this QA Agreement to be signed and delivered by their duly authorized representatives on the dates set forth below in duplicate, each of which will be treated for all purposes as an original. 

 

																	
	RTI Biologics, Inc.	 		 		 		 	      Zimmer Dental, Inc.

																	
								
	By:	 	  
	 		 		 	                    By:	 	  
	 		 	

																	
							
	Name/Title:	 	  
	 		 		 	Name/Title:	 	  
	 	

																	
						
	Date:	 	  
	 		 		 	                    Date:	 	  

  
 Schedule A

 Contact information for responsibilities listed in this Quality Agreement 

 

							
	 Zimmer Function
	 	 Phone Number
	 	 RTI Function
	 	 Phone Number

				
	Regulatory Affairs	 	760-929-4110	 	Regulatory Affairs	 	386-418-8888
				
	MarComm	 	760-929-4300	 	Quality Systems	 	386-418-8888

  
 Schedule B

 Return Procedures 
  

	—	 	 For any Implant return, contact the RTI Customer Service Department at +1 386-418-8888 to receive a Return Authorization Number.

  

	—	 	 All returns require the following: 

  

	 	(a)	the 7 digit serial Identification number(s) (Note: If the number is unknown, all possible numbers that could be applicable to the returned item(s) must be provided);

  

	 	(b)	the original packaging; and 

  

	 	(c)	a detailed explanation of the reason for the return. 

  

	—	 	 The Return Authorization Number must be marked on the outside of the shipping package before shipping to RTI. 

 

	—	 	 All opened Implant(s) must be treated as potential biohazards and must be shipped according to applicable shipping guidelines. The items must be placed
in a doubled leak-proof bag labeled and designed for biohazardous material. The outer (second) bag should be protected from potential contamination. The double-bagged items should then be placed into a sturdy outer package of corrugated fiberwood,
wood, metal or rigid plastic of a minimum size of 7”x4”x2”. This can be a plain cardboard box or FedEx Clinical Pack. 

  

	—	 	 Any opened Implant(s) that have been exposed to a known infectious disease will need to be packaged in conjunction with IATA, DOT, FAA, OSHA and CDC
packing instruction guidelines for shipping known infectious disease substances, and this information must be conveyed to customer service. 

  

			
	SHIP TO:	 	RTI Biologics, Inc.
		 	Attn: Returns
		 	11621 Research Circle
		 	Alachua, Florida, USA 32615
		 	Telephone: (386) 418-8888
	
	or, if applicable,
		
		 	Tutogen Medical GmbH
		 	Attn: Returns
		 	Industriestraße 6
		 	91077 Neunkirchen am Brand
		 	Deutschland
		 	Telephone: +49 (91 34) 99 88 - 0Employment Agreement - Jeffrey P. Winter

  
 EXHIBIT 10.3

 EMPLOYMENT AGREEMENT 
 This EMPLOYMENT AGREEMENT is made and is effective as of the 1st day of November, 2010 (the “Effective Date”), by and between Kindred Healthcare Operating, Inc., a Delaware corporation (the
“Company”), and Jeffrey P. Winter (the “Executive”). 
 W I T N E S
S E T H: 
 WHEREAS, the Executive is employed by the Company, a wholly-owned subsidiary of Kindred
Healthcare, Inc. (“Parent”), and the parties hereto desire to provide for the terms of Executive’s employment by the Company; and 
 WHEREAS, the Executive Compensation Committee of the Board of Directors of the Parent has determined that it is in the best interests of the Company and Parent to enter into this Agreement. 

NOW, THEREFORE, in consideration of the premises and the respective covenants and agreements contained herein, and intending to be
legally bound hereby, the Company and Executive agree as follows: 
 1. Employment. The Company hereby agrees to employ
Executive and Executive hereby agrees to be employed by the Company on the terms and conditions herein set forth. The initial term of this Agreement shall be for a one-year period commencing on the Effective Date. The term shall be automatically
extended by one additional day for each day beyond the Effective Date that the Executive remains employed by the Company until such time as the Company elects to cease such extension by giving written notice of such election to the Executive (the
“Term”) specifying the effective date of such notice. In such event, the Agreement shall terminate on the first anniversary of the effective date of such election notice. 

2. Duties. Executive is engaged by the Company as Executive Vice President and President, Hospital Division, reporting directly to
Benjamin A. Breier, Chief Operating Officer. 
 3. Extent of Services. Executive, subject to the direction and control of
the Board of Directors (the “Board”), shall have the power and authority commensurate with his executive status and necessary to perform his duties hereunder. During the Term, Executive shall devote his entire working time, attention,
labor, skill and energies to the business of the Company, and shall not, without the consent of the Company, be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary
advantage. 

  
 4.
Compensation. As compensation for services hereunder rendered, Executive shall receive during the Term: 

(a) A base salary (“Base Salary”) of $460,000 per year payable in equal installments in accordance with the
Company’s normal payroll procedures. Executive may receive increases in his Base Salary from time to time, as approved by the Board. 
 (b) In addition to Base Salary, Executive shall be entitled to receive bonuses and other incentive compensation as the Board may approve from time to time, including participation in the Company’s
annual short-term incentive compensation plan and its long-term incentive compensation plan, in accordance with the terms and conditions of such plans as may be in effect from time to time. For 2010, the Executive will not participate in the
short-term incentive compensation plan or the long-term incentive compensation plan. 
 5. Benefits. 

(a) Executive shall be entitled to participate in any and all pension benefit, welfare benefit (including, without
limitation, medical, dental, disability and group life insurance coverages) and fringe benefit plans from time to time in effect for officers of the Company and its affiliates following the Company’s standard waiting periods, if any. Until the
time of eligibility, the Company will reimburse Executive for the difference between the cost of maintaining COBRA coverage under Executive’s present medical insurance plan and the cost of coverage under the medical plan selected by Executive
as an employee of the Company. 
 (b) Executive shall be entitled to participate in such bonus, stock option, or
other incentive compensation plans of the Company and its affiliates in effect from time to time for officers of the Company. At the next regularly scheduled meeting of the Board of Directors of the Parent, the Chief Executive Officer will recommend
that Executive be granted 20,000 shares of restricted stock that will vest in equal annual installments over four years. The equity grants would be subject to the terms and conditions of the Kindred Healthcare, Inc. 2001 Stock Incentive Plan,
Amended and Restated, and the applicable award agreement related thereto. 
 (c) In addition to Company holidays,
Executive shall be entitled to earn paid time off of up to a maximum of 208 hours per year subject to the Company’s policies, in effect from time to time. The Executive shall schedule the timing of such paid time off in a reasonable manner. The
Executive also may be entitled to such other leave, with or without compensation, as shall be mutually agreed by the Company and Executive. 
 (d) Executive may incur reasonable expenses for promoting the Company’s business, including expenses for entertainment, travel and similar items. The Company shall reimburse Executive for all such
reasonable expenses in accordance with the Company’s reimbursement policies and procedures, as may be in effect from time to time. 

  
 2 

  
 (e) The
Company shall reimburse all reasonable travel and relocation expenses incurred by Executive in accordance with the Company’s VP Relocation Policy. In the event Executive voluntarily terminates his employment with the Company without Good Reason
within one year from the Effective Date, Executive will reimburse the Company for a pro rata amount of Executive’s relocation expenses and other amounts paid under the Company’s VP Relocation Policy and/or this Section 5(e).

 (f) With the Executive’s first regular paycheck, Executive will receive a one-time, sign-on bonus of
$100,000. In addition, in consideration of the settlement costs related to the purchase of a new home, Executive will receive a one-time $75,000 lump-sum stipend, also payable in Executive’s first paycheck. In the event Executive voluntarily
terminates his employment with the Company without Good Reason within one year of the Effective Date, Executive will reimburse the Company the full amount of the sign-on bonus and the stipend. 

6. Termination of Employment. 
 (a) Death or Disability. Executive’s employment shall terminate automatically upon Executive’s death during the Term. If the Company determines in good faith that the Disability of
Executive has occurred during the Term (pursuant to the definition of Disability set forth below) it may give to Executive written notice of its intention to terminate Executive’s employment. In such event, Executive’s employment with the
Company shall terminate effective on the 30th day after receipt of such notice by Executive (the “Disability Effective Date”), provided that, within the 30 days after such receipt, Executive shall not have returned to full-time performance
of Executive’s duties. For purposes of this Agreement, “Disability” shall mean Executive’s absence from Executive’s full-time duties hereunder for a period of 90 days due to disability as defined in the long-term disability
plan provided to the Executive by the Company. 
 (b) Cause. The Company may terminate Executive’s
employment during the Term for Cause. For purposes of this Agreement, “Cause” shall mean the Executive’s (i) conviction of, guilty plea, or plea of nolo contendere to a crime involving moral turpitude; or
(ii) willful and material breach by Executive of his duties and responsibilities, which is committed in bad faith or without reasonable belief that such breaching conduct is in the best interests of the Company and its affiliates, but with
respect to clause (ii) only if the Board adopts a resolution by a vote of at least 75% of its members so finding after giving the Executive and his attorney an opportunity to be heard by the Board and a reasonable opportunity of not less than
30 days to remedy or correct the purported breaching conduct. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the Board or based upon advice of counsel for the Company shall be conclusively presumed to
be done, or omitted to be done, by Executive in good faith and in the best interests of the Company. 

  
 3 

  
 (c)
Good Reason. Executive’s employment may be terminated during the Term by Executive for Good Reason. “Good Reason” shall exist upon the occurrence, without Executive’s express written consent, of any of the following
events: 
 (i) a material adverse change in Executive’s authority, duties or responsibilities (including,
without limitation the Company assigning to Executive duties of a substantially nonexecutive or nonmanagerial nature) (other than any such change directly attributable to the fact that the Company is no longer publicly owned); 

(ii) the Company shall materially reduce the Base Salary or annual bonus opportunity of Executive; 

(iii) the Company shall require Executive to relocate Executive’s principal business office more than 30 miles from
the location of such office on the Effective Date which the Executive acknowledges is 680 South Fourth Street, Louisville, Kentucky; or 
 (iv) a material breach by the Company of Section 5(a) or Section 9(c) of this Agreement. 
 For purposes of this Agreement, “Good Reason” shall not exist until after Executive has given the Company notice of the applicable event within 90 days of the initial occurrence of such event
and which is not remedied within 30 days after receipt of written notice from Executive specifically delineating such claimed event and setting forth Executive’s intention to terminate employment if not remedied; provided, that if the
specified event cannot reasonably be remedied within such 30-day period and the Company commences reasonable steps within such 30-day period to remedy such event and diligently continues such steps thereafter until a remedy is effected, such event
shall not constitute “Good Reason” provided that such event is remedied within 60 days after receipt of such written notice. 
 (d) Notice of Termination. Any termination by the Company for Cause, or by Executive for Good Reason, shall be communicated by Notice of Termination given in accordance with this Agreement. For
purposes of this Agreement, a “Notice of Termination” means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) sets forth in reasonable detail the facts and circumstances
claimed to provide a basis for termination of Executive’s employment under the provision so indicated and (iii) specifies the intended termination date (which date, in the case of a termination for Good Reason, shall be not more than
thirty days after the giving of such notice). The failure by Executive or the Company to set forth in the 

  
 4 

 
Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of Executive or the Company, respectively, hereunder or preclude
Executive or the Company, respectively, from asserting such fact or circumstance in enforcing Executive’s or the Company’s rights hereunder. 
 (e) Date of Termination. “Date of Termination” means (i) if Executive’s employment is terminated by the Company for Cause, or by Executive for Good Reason, the later of the date
specified in the Notice of Termination or the date that is one day after the last day of any applicable cure period, (ii) if Executive’s employment is terminated by the Company other than for Cause or Disability, or Executive resigns
without Good Reason, the Date of Termination shall be the date on which the Company or Executive notified Executive or the Company, respectively, of such termination and (iii) if Executive’s employment is terminated by reason of death or
Disability, the Date of Termination shall be the date of death of Executive or the Disability Effective Date, as the case may be. 
 7. Obligations of the Company Upon Termination. Following any termination of Executive’s employment hereunder, the Company shall pay Executive his Base Salary through the Date of Termination
and any amounts owed to Executive pursuant to the terms and conditions of the benefit plans and programs of the Company at the time such payments are due. In addition, subject to Section 7(e) hereof and the conditions set forth below, Executive
shall be entitled to the following additional payments: 
 (a) Death or Disability. If, during the Term,
Executive’s employment shall terminate by reason of Executive’s death or Disability, the Company shall pay to Executive (or his designated beneficiary or estate, as the case may be) the prorated portion of any Target Bonus (as defined
below) Executive would have received for the year of termination of employment. Such amount shall be paid on the date when such amounts would otherwise have been payable to the Executive if Executive’s employment with the Company had not
terminated as determined in accordance with the terms and conditions of the applicable short-term incentive plan of the Company. 
 For purposes of this Agreement: “Target Bonus” shall mean the full amount of the targeted annual short-term incentive bonus that would be payable to the Executive, assuming the targeted
performance criteria on which such annual short-term incentive bonus is based were deemed to be satisfied, in respect of services for the calendar year in which the date in question occurs. 

(b) Good Reason; Other than for Cause. If, during the Term, the Company shall terminate Executive’s employment
other than for Cause (but not for Disability), or the Executive shall terminate his employment for Good Reason: 

(1) in satisfaction of the annual bonus Executive would otherwise be eligible to receive under the short-term incentive
plan in respect of the calendar 

  
 5 

 
year in which the Date of Termination occurs, the Company shall pay to Executive an amount equal to the product of (i) the annual bonus, if any, to which the Executive would have been
entitled for the year in which the Date of Termination occurs had Executive’s employment with the Company not been terminated, as determined in accordance with the terms and conditions of the applicable short-term incentive plan of the Company
as provided in Section 4(b) hereof, and (ii) a fraction, the numerator of which is the number of days in the period beginning on the first day of the calendar year in which the Date of Termination occurs and ending on the Date of
Termination and the denominator of which is 365. Such amount shall be paid on the date when such amounts would otherwise have been payable to the Executive if Executive’s employment with the Company had not terminated as determined in
accordance with the terms and conditions of the applicable short-term incentive plan of the Company. 
 (2)
Within 14 days following Executive’s Date of Termination, the Company shall pay to Executive a cash severance payment in an amount equal to 1.5 times the sum of the Executive’s Base Salary and Target Bonus as of the Date of Termination.

 (3) For a period of 18 months following the Date of Termination (the “Benefit Continuation Period”),
the Executive shall be treated as if he had continued to be an Executive for all purposes under the Company’s health insurance plan and dental insurance plan; or if the Executive is prohibited from participating in such plans, the Company or
Parent shall otherwise provide such benefits. Executive shall be responsible for any employee contributions for such insurance coverage. Following the Benefit Continuation Period, the Executive shall be entitled to receive continuation coverage
under Part 6 of Title I of ERISA (“COBRA Benefits”) by treating the end of this period as the applicable qualifying event (i.e., as a termination of employment) for the purposes of ERISA Section 603(2)) and with the concurrent loss of
coverage occurring on the same date, to the extent allowed by applicable law. 
 (4) For the Benefit Continuation
Period, Company shall maintain in force, at its expense, the Executive’s life insurance in effect under the Company’s voluntary life insurance benefit plan as of the Date of Termination. Executive shall be responsible for any employee
contributions for such insurance coverage. For purposes of clarification, the portion of the premiums in respect of such voluntary life insurance for which Executive and Company are responsible, respectively, shall be the same as the portion for
which Company and Executive are responsible, respectively, immediately prior to the Date of Termination. 
 (5)
Within fifteen (15) days after the Date of Termination, the Company shall pay to Executive a cash payment in an amount, if any, necessary to compensate Executive for the Executive’s unvested interests under the Company’s retirement
savings plan which are forfeited by Executive in connection with the termination of Executive’s employment. 

  
 6 

  
 (6)
Company may adopt such amendments to its executive benefit plans, if any, as are necessary to effectuate the provisions of this Agreement. 
 (7) Any outstanding unvested stock options, stock performance units or similar equity awards (other than restricted stock awards) held by Executive on the Date of Termination shall continue to vest in
accordance with their original terms (including any related performance measures) for the duration of the Benefit Continuation Period as if Executive had remained an employee of the Company through the end of such period and any such stock option,
stock performance unit or other equity award (other than restricted stock awards) that has not vested as of the conclusion of such period shall be immediately cancelled and forfeited as of such date. In addition, Executive shall have the right to
continue to exercise any outstanding vested stock options held by Executive during the Benefit Continuation Period; provided that in no event shall Executive be entitled to exercise any such option beyond the original expiration date of such option.
Any outstanding restricted stock award held by Executive as of the Date of Termination that would have vested during the Benefit Continuation Period had Executive remained an employee of the Company through the end of such period shall be
immediately vested as of the Date of Termination and any restricted stock award that would not have vested as of the conclusion of such period shall be immediately cancelled and forfeited as of such date. 

(8) Notwithstanding anything in this Agreement to the contrary, in no event shall the provision of in-kind benefits
pursuant to this Section 7 during any taxable year of Executive affect the provision of in-kind benefits pursuant to this Section 7 in any other taxable year of Executive. 

(9) Following the Executive’s Date of Termination, the Executive shall receive the computer which Executive is
utilizing as of the Date of Termination. 
 (c) Cause; Other than for Good Reason. If Executive’s
employment shall be terminated for Cause or Executive terminates employment without Good Reason (and other than due to such Executive’s death) during the Term, this Agreement shall terminate without further additional obligations to Executive
under this Agreement. 
 (d) Death after Termination. In the event of the death of Executive during the
period Executive is receiving payments pursuant to this Agreement, Executive’s designated beneficiary shall be entitled to receive the balance of the payments; or in the event of no designated beneficiary, the remaining payments shall be made
to Executive’s estate. 

  
 7 

  
 (e)
General Release of Claims. Notwithstanding anything herein to the contrary, the amounts payable pursuant to this Section 7 are subject to the condition that Executive has delivered to the Company an executed copy of an irrevocable
general release of claims in a form satisfactory to the Company within the 60 day period immediately following the Executive’s separation from service (the “Release Period”). Any payment that otherwise would be made prior to
Executive’s delivery of such executed release pursuant to this Section 7 shall be paid on the first business day following the conclusion of the Release Period; provided that in-kind benefits provided pursuant to subsections (b)(3) and
(4) of this Section 7 shall continue in effect after separation from service pending the execution and delivery of such release for a period not to exceed 60 days; provided further that if such release is not executed and delivered within
such 60-day period, Executive shall reimburse the Company for the full cost of coverage during such period. 

(f) Six Month Delay for Specified Employees. Notwithstanding anything herein to the contrary, if at the time of
Executive’s separation from service Executive is a “specified employee” as defined in Section 409A of the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder (the “Code”) and the
deferral of the payment payable pursuant to Section 7(b)(2) is necessary in order to prevent any accelerated or additional tax under Section 409A of the Code, then the payment to which Executive would otherwise be entitled during the first
six months following Executive’s separation from service shall be deferred and accumulated (without any reduction in such payment ultimately paid to Executive) for a period of six months from the date of separation from service and paid in a
lump sum on the first day of the seventh month following such separation from service (or, if earlier, the date of Executive’s death), together with interest during such period at a rate computed by adding 2.00% to the Prime Rate as published
in the Money Rates section of the Wall Street Journal, or other equivalent publication if the Wall Street Journal no longer publishes such information, on the first publication date of the Wall Street Journal or equivalent publication after the date
of Executive’s separation from service (provided that if more than one such Prime Rate is published on any given day, the highest of such published rates shall be used). 
 8. Disputes. Any dispute or controversy arising under, out of, or in connection with this Agreement shall, at the election and upon written demand of either party, be finally determined and settled
by binding arbitration in the City of Louisville, Kentucky, in accordance with the Labor Arbitration rules and procedures of the American Arbitration Association, and judgment upon the award may be entered in any court having jurisdiction thereof.
The Company shall pay all costs of the arbitration and all reasonable attorneys’ and accountants’ fees of the Executive in connection therewith, including any litigation to enforce any arbitration award. 

  
 8 

  
 9. Successors.

 (a) This Agreement is personal to Executive and without the prior written consent of the Company shall not be
assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by Executive’s legal representatives. 

(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 (c) The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or
otherwise) to all or substantially all of the business and/or assets of the Company, or any business of the Company for which Executive’s services are principally performed, to assume expressly and agree to perform this Agreement in the same
manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or
assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise. 
 10. Other
Severance Benefits. Executive hereby agrees that in consideration for the payments to be received under Section 7(b) of this Agreement, Executive waives any and all rights to any payments or benefits under any severance plans or
arrangements of the Company or their respective affiliates that specifically provide for severance payments, other than the Change in Control Severance Agreement between the Company and Executive (the “Change in Control Severance
Agreement”); provided that any payments payable to Executive under Section 7(b) hereof shall be offset by any payments payable under the Change in Control Severance Agreement. 

11. Withholding. All payments to be made to Executive hereunder, including, without limitation, those payments under
Section 5, will be subject to all applicable required withholding of taxes. 
 12. No Mitigation. Executive shall
have no duty to mitigate his damages by seeking other employment and, should Executive actually receive compensation from any such other employment, the payments required hereunder (including, without limitation, the provision of in-kind benefits
provided under Section 7(b) hereof) shall not be reduced or offset by any such compensation. Further, the Company’s and Parent’s obligations to make any payments hereunder shall not be subject to or affected by any setoff,
counterclaims or defenses which the Company or Parent may have against Executive or others. 
 13. Non-solicitation.
During the Term and for a period of one year thereafter (collectively, the “Non-solicitation Period”), Executive shall not directly or indirectly, individually 

  
 9 

 
or on behalf of any person other than the Company, aid or endeavor to solicit or induce any of the Company’s or its affiliates’ employees to leave their employment with the Company or
such affiliates in order to accept employment with Executive or any other person, corporation, limited liability company, partnership, sole proprietorship or other entity. If the restrictions set forth in this section would otherwise be determined
to be invalid or unenforceable by a court of competent jurisdiction, the parties intend and agree that such court shall exercise its discretion in reforming the provisions of this Agreement to the end that the Executive will be subject to a
non-solicitation covenant which is reasonable under the circumstances and enforceable by the Company. It is agreed that no adequate remedy at law exists for the parties for violation of this section and that this section may be enforced by any
equitable remedy, including specific performance and injunction, without limiting the right of the Company to proceed at law to obtain such relief as may be available to it. The running of the Non-solicitation Period shall be tolled for any period
of time during which Executive is in violation of any covenant contained herein, for any reason whatsoever. This Section 13 shall survive this Agreement. 
 14. Notices. Any notice required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given when delivered or sent by telephone facsimile
transmission, personal or overnight couriers, or registered mail with confirmation or receipt, addressed as follows: 
 If to
Executive: 
 Jeffrey P. Winter 
 680 South Fourth Street 
 Louisville, KY 40202 

If to Company: 
 Kindred Healthcare Operating, Inc. 
 680 South Fourth Street 

Louisville, KY 40202 
 Attn: General Counsel 
 15. Waiver of Breach and Severability. The waiver
by either party of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by either party. In the event any provision of this Agreement is found to be invalid or
unenforceable, it may be severed from the Agreement and the remaining provisions of the Agreement shall continue to be binding and effective. 
 16. Entire Agreement; Amendment. This instrument contains the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, promises, covenants,
arrangements, communications, representations and warranties between them, whether written or oral with respect to the subject matter hereof. No provisions of this Agreement may be modified, waived or discharged unless such modification, waiver or
discharge is agreed to in writing signed by Executive and such officer of the Company specifically designated by the Board. 

  
 10 

  
 17. Governing
Law. This Agreement shall be construed in accordance with and governed by the laws of the State of Delaware. 
 18.
Headings. The headings in this Agreement are for convenience only and shall not be used to interpret or construe its provisions. 
 19. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

 20. Survival. Any provision of this Agreement creating obligations extending beyond the Term of this Agreement shall
survive the expiration or termination of this Agreement, regardless of the reason for such termination. 
 21.
Section 409A. If any provision of this Agreement (or any award of compensation or benefits provided under this Agreement) would cause Executive to incur any additional tax or interest under Section 409A of the Code, the Company
shall reform such provision to comply with 409A and agrees to maintain, to the maximum extent practicable without violating 409A of the Code, the original intent and economic benefit to Executive of the applicable provision; provided that nothing
herein shall require the Company to provide Executive with any gross-up for any tax, interest or penalty incurred by Executive under Section 409A of the Code. 

  
 11 

  
 IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first above written. 
  

			
	KINDRED HEALTHCARE OPERATING, INC.
		
	By:	 	 /s/ Paul J. Diaz

		 	Paul J. Diaz
		 	President and Chief Executive Officer
	
	Solely for the purpose of Section 7
	
	KINDRED HEALTHCARE, INC.
		
	By:	 	 /s/ Paul J. Diaz

		 	Paul J. Diaz
		 	President and Chief Executive Officer
	
	   /s/ Jeffrey P. Winter

	JEFFREY P. WINTER

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]